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ABSTRACT

The wide use of the f-elements, including nuclear weapons, nuclear energy and
radiopharmaceuticals, has led to the growing unwanted accumulation of the lanthanides
and actinides in the environment. The removal of these metals requires the design of
highly selective ligands that take advantage of their complex chemistry (wide degree of
covalency and high coordination numbers). Additionally, the environments these metals
are typically being removed from involve a complicated mixture of other metals and
strong counterions. Ligand design for the f-elements requires high selectivity and the
formation of stable complexes in a wide range of environments.

Ethylene diamine tetraacetic acid (EDTA) is one of the most well-known and widely
utilized ligands in coordination chemistry, and hydroxamate-containing ligands are some
of the most common in biological chemistry, suggesting a natural combination of EDTAlike backbones with hydroxamate arms. Specifically, the increase from the hexadentate
EDTA to the decadentate hydroxamate analog would address the larger coordination
numbers of the f-elements. EDTA, however, is too small even for Fe(III), leaving a
coordinated water on the Fe, and is far too small for Ln/An(III) ions. Consequently, I
synthesized a hydroxamate EDTA analog where the arms are longer by one carbon
(ethylenediamine tetrapropionyl hydroxamic acid, EDTPHA). Potentiometric titrations
of EDTPHA with La(III), Eu(III), and Lu(III), and a comparison with a synthetic allcarboxylate analog (EDTP) reveal that EDTPHA is powerful ligand for lanthanides
competitive with EDTA.

ii

During the course of the work I developed a new protecting group for use in
hydroxamate synthesis, and the straightforward synthesis of the EDTPHA ligand
(utilizing highly pure aza-Michael chemistry) enables future work with additional ligands
including EDTA-like ligands as well as siderophore-like peptide ligands to optimize their
selectivity for f-element chemistry.
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CHAPTER ONE

BEYOND BIOLOGICAL CHELATION: F-ELEMENT COORDINATION BY
POLYHYDROXAMATE LIGANDS

Abstract: The promise of polyhydroxamic acid ligands for the selective chelation of the felements is becoming increasingly more apparent. The initial studies of polyhydroxamic acid
siderophores showed the formation of highly stable complexes with Pu(IV), but a higher
preference for Fe(III) hindered effective applications. The development of synthetic routes toward
highly pure and customizable ligands containing multiple hydroxamic acids allowed for the
growth of new classes of compounds. While the first round of these ligands focused on the
incorporation of siderophore-like frameworks, the new synthetic strategies led to small molecules
of various frameworks and even resins for applications in the field of f-element separations and
biological desorption. Unfortunately, a lack of consistent stability constant data makes direct
comparisons across this body of work difficult. More studies into the stability constants and
separations of the f-elements in a variety of pH ranges is necessary to truly realize the potential
for polyhydroxamic acid ligands.

Introduction

The f-elements are utilized in a variety of applications, including nuclear weapons, nuclear
energy and radiopharmaceuticals.1–4 These applications, as well as the unwanted accumulation of
lanthanides and actinides in the environment, necessitate advances in understanding and
exploitation of their basic coordination chemistry. The f-elements display a broad range of
oxidation states, wide degree of covalency, high coordination numbers, and variable coordination
environments which make the area ripe for advances in ligand design.1–3,5 Increased exposure of
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the public to these metals, along with a growing demand for their availability by the technology
and energy industries, require the design of highly selective ligands capable of the formation of
stable complexes with the f-elements.5–9

Siderophores, biological scavengers primarily of iron(III), are strongly chelating polydentate
ligands, often with preorganized binding pockets tuned for metal selectivity. Siderophores have
often been used as the basis for actinide ligand design due to the similar charge/ionic radius ratio
between iron(III) (4.2 e/Å) and plutonium(IV) (4.6 e/Å).1,2,10,11 Ferrichrome (Figure 1.1), the first
isolated and characterized siderophore, contains three bidentate hydroxamic acid moieties,
making it a strong chelator of the ferric ion. Consequently, hydroxamic acids have long been
investigated as potent actinide ligands.2,11,12

Siderophores provide high affinity and selectivity, enabling separation of metal ions from
other metals or coordinating ions, as well as the removal of metals from complex environments,
such as groundwater or biological systems. Such selectivity could prove highly advantageous in
controlling the complicated chemistry of the f-elements in their array of applications. This article
introduces the hydroxamic acid functional group and the naturally-occurring polyhydroxamic
acid-containing siderophores, then reviews some of the polyhydroxamic ligands that have been
reported and their uses with the f-elements.

Hydroxamic acids
The hydroxamic acid (HA) class of compounds was discovered in 1869 by H. Lossen’s study
of the reaction between ethyl oxalate and hydroxylamine, producing oxalohydroxamic acid
(Scheme 1).13 Hydroxamic acids (HA), with the structure -RC(O)NHOH, are bidentate analogs of
the biologically/environmentally ubiquitous monodentate carboxylates (-RC(O)OH). However, a
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lack of understanding of the structure of hydroxamic acids in solution hindered developmental
research until the mid-20th century, when multiple HA-containing siderophores were isolated.14
Two siderophores of note, the linear desferrioxamine (DFOB, Figure 1.1) and the cyclic
ferrichrome, both contain three HA residues, making them powerful iron chelators.15–18

Scheme 1.1. Reaction of ethyl oxalate and hydroxylamine to form oxalohydroxamic acid. 19

N-acylated hydroxylamines, more commonly called hydroxamic acids, are known to exist in
two distinct tautomeric forms, the keto and enol form (Scheme 2). The keto form is believed to
predominate in solid and solution state.13,20–22 Hydroxamic acids are weakly acidic, primarily due
to the -OH group (pKa 8-9). They are weaker acids than their corresponding carboxylic acids
(pKa 4-5), but more acidic than the amides (pKa 20-22).23,24

Scheme 1.2. Possible protonated forms of hydroxamic acid.

Hydroxamic acids are capable of acting as mono- or bidentate ligands through the oxygen
atoms, but can more rarely also act as monodentate ligands through the nitrogen atom, if
unsubstituted.18,25 The loss of a proton from the hydroxy group, followed by a ring closing by the
carbonyl allows for the formation of a stable five-membered metallacycle during metal
coordination.26 Some metal-HA complexes are highly colored and have been used in the
spectrophotometric and gravimetric analysis of the involved metals.25–27 Due to the neutral charge
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of many hydroxamate-metal complexes, they can be extracted from aqueous systems by many
immiscible organic solvents.26,28,29

Siderophores

Siderophores are low molecular weight, iron(III) chelators synthesized by microorganisms in
low-iron environments, containing, most commonly, catecholate or hydroxamate groups. They
help solubilize iron oxides and transport the resultant iron ions into microorganism cells. The
high stability of the Fe(III)-siderophore complexes complicates the dissociation of the Fe(III) for
use in the cell. There are several known pathways, which are typically specific to the siderophore
involved. These pathways typically involve membrane-recognition of the complex and
subsequent transport into the cell, where a change in environment is involved in the dissociation
of the Fe(III) ion, or reductive actions at the cell membranes.30–34

The coordination of Fe(III) by hydroxamic acid-containing siderophores leads to similar
coordination properties as when Fe(III) is bound by three unlinked hydroxamates. In both cases,
the Fe(III) core is bound in an octahedral geometry and is high-spin, thermodynamically stable,
and labile. The hydroxamic acid moieties form stable, five-membered rings with the Fe(III) ion
through primarily electrostatic interactions.

Ferrichrome binds Fe(III) with a stability constant about ten times that of EDTA and is highly
selective for the Fe(III) ion.17 Synthetic analogs of ferrichrome and DFO have been heavily
studied for possible medicinal applications.35–38 Desferal, desferrioxamine mesylate (DFOM), was
approved by the FDA in the mid-20th century for the treatment of iron overload and thalassemia.
Desferal helps solubilize biological iron(III), which is then excreted from the body. However,
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Desferal is not orally active and requires prolonged intravenous delivery, drastically decreasing
its efficacy at the removal of iron(III) from the body.39–42

The difficulty of cyclizing peptides has hindered the synthesis of peptide analogs of
ferrichrome. Another major roadblock was the difficult synthesis of high purity hydroxamatecontaining building blocks due to incomplete conversion of starting materials, such as carboxylic
acids and subsequent characterization difficulties. One attempt at circumscribing this issue was
performed by Maurer et al., who utilized O-benzylhydroxylamines and subsequent alkylation of
the amine in the hydroxamic acid to prevent unwanted side products from forming.43,44

New approaches to the treatment of iron overload diseases were realized through the use of
synthetic siderophores.45,46 Traditionally, these synthetic compounds were designed around the
common subunits found in the naturally occurring siderophores. For example, several synthetic
ferrichrome analogues have been reported.32,35,36,47–49 The analogues are related by the inclusion of
three hydroxamic acid groups bridging from a central backbone. Compounds such as BAMTPH50
and MEDROX46 utilize a rigid tri-substituted benzene backbone, while others, such as
TRENDROX46, TAGP, and TAGE51,52 utilize a more flexible TREN anchor. Recent work by
Crumbliss and coworkers showed a saccharide backbone was effective in the synthesis of
ferrichrome mimics.32,53 Control of the backbone or anchor allows for direct control over the
tuning of the binding pocket of the hydroxamic acid groups.35,51 Many studies have shown that
the backbone does not directly affect the chelation ability of these siderophore analogues, so
much research has focused more on the hydroxamate arms and the terminal groups (e.g.
substituted versus unsubstituted hydroxamate units).35–37,54–57
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Siderophore analogues

The development of synthetic siderophores allowed for a wide variety of well-studied ligand
scaffolds to be tuned for the coordination of specific metals, such as Pu(IV). DFOM was an early
attempt for chelation therapy in case of Pu(IV) contamination (Figure 1.1).2 However, DFOM
removal of Pu(IV) from plasma proteins in vivo proved to be similarly as effective as DTPA.
Metabolic destruction and rapid renal clearance prevented DFOM from being more effective. 58–60
Further investigation showed DFOM to be an ineffective chelator of trivalent actinides and
lanthanides.59,60

Figure 1.1. Structures of naturally occurring trihydroxamate-containing siderophores, ferrichrome,
desferrioxamine E (DFOE), desferrioxamine B (DFOB), and deferoxamine mesylate (DFOM).

Flow-injection ESI-MS (FI-ESI-MS) was used to investigate the affinity of ferrichrome and
DFOB for Th(IV). Ferrichrome was five times more effective at Th(IV) coordination than DFOB.
The inverse was measured for Fe(III). More interestingly, when in the presence of Fe(III) or a
cation-exchange method, the Th(IV) core was rapidly exchanged. Desporption of the Th(IV) in
the presence of anionic binding sites suggests a possible route toward Th(IV) impediment in
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environmental conditions through adsorption onto anionic binding sites, such as anionic minerals.
This finding demonstrated that the presence of siderophores in soil conditions does not
necessarily lead to increased mobility of Th(IV) ions due to its preference for interaction with
anionic sorbents over the siderophore framework, specifically DFO in this case.61

The presence of siderophores with affinity for Pu(IV) or other potentially toxic metals can
drastically affect their bioavailability, solubility and accumulation in soil and groundwater.9,62,63
Siderophores, ferrioxamines in particular, are estimated to be found in soils at concentrations
from 0.01-0.1 μM.62,63 The Pu(IV)-DFOB complex was shown to be taken up into the bacteria
Microbacterium flavenscens by the same recognition mechanism as the Fe(III)-DFOB complex.
The two metals were also shown to be in competition for binding sites in the uptake proteins.64
DFOM and pyoverdine siderophore, a mixed catechol/hydroxamic acid siderophore, were shown
to bind Th(IV), U(VI) and Pu(IV) through the dissolution of spent nuclear fuel pellets. 65 DFOB
and the tetrahydroxamate analogue DFO-HOPO (Figure 1.1) were investigated for their ability to
prevent the adsorption of Pb(II) and Eu(III) onto goethite and boehmite through the solubilization
of the metal ions. The high specificity of DFOB for Th(IV) (logK=30.6) and Pu(IV) (logK=38.8)
combats the coordination of competitive metals (e.g. Ca2+).66

Small molecules

The larger radii of the f-elements allow for higher coordination numbers (8-12) than are seen
with the transition metals. For this reason, the bidentate hydroxamic acid moiety shows high
affinity for the f-elements, as seen through the studies of naturally-occurring siderophores and
Pu(IV). However, the structural limitations of natural siderophores (e.g. ferrichrome and
desferrioxamine), combined with difficult synthesis of direct analogues, led researchers to focus
investigation on the incorporation of HA binding moieties into various commercially available
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backbones. Both aliphatic and aromatic (1,2-HOPO, Figure 1.2) hydroxamic acids in a multitude
of backbones have been heavily studied with the lanthanides and actinides.
Motekaitis, Murase and Martell published the synthesis of N,N’-ethylenediaminediaceticN,N’-diacethydroxamic acid (EDTA-DX, I) and potentiometric titrations with Mg(II), Fe(III),
Co(II), Ni(II), Cu(II) and Zn(II).67 Later, Martell et al. published work with a trihydroxamate
ligand,

N,N’,N”-tris[2-N-hydroxycarbamoyl)ethyl]-1,3,5-benzenetricarboxamide

(BAMPTH,

XII). This ligand featured three hydroxamic acid residues on a benzene backbone. Potentiometric
titrations with Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Ga(III) and Al(III) showed that with trivalent
metals, all three arms interacted during bonding, but with divalent metals, only two arms
interacted.50 The lack of chelate effect with these polyhydroxamic acids was also noted, in
agreement with previous work by Raymond and Schwarzenbach.31,57 The tetrahydroxamate
derivative of EDTA (II) was reported by Karlicek and Majer in 1972. This ligand was shown to
preferentially form a 1:1 complex with Cu(II) and Fe(III) despite variations of ligand:metal ratios,
also demonstrating the lack of chelate effect noted by Schwarzenbach.68

Figure 1.2. Structure of aliphatic and aromatic hydroxamic acid moiety.
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Table 1.1. Stability constant data for ligands XI and III (n=4,6,7,8).69
III

H+

Reaction

XI

n=4

n=6

n=7

n=8

[HL]/[H+][L]

10.04

9.38

9.61

9.65

9.52

9.33

8.81

8.92

9.02

8.82

L]/[HL][H+]

[H2

[H3L]/[H2

L+][H+]

8.48

Fe(III)

[ML]/[M][L]

26.32

17.60

18.01

20.08

20.30

La(III)

[ML]/[M][L]

14.42

9.01

9.59

9.98

10.33

Nd(III)

[ML]/[M][L]

16.70

Yb(III)

[ML]/[M][L]

18.08

Th(IV)

[ML]/[M][L]

16.36

UO22+

[ML]/[M][L]

13.27

12.95

13.07

13.28

[MHL]/[ML][H]

17.50

17.50

17.48

16.92

Pu(IV)

[ML]/[M][L]

18.44

30.0[b]

[a] All data reported at 25°C and μ=0.1 NaNO3. [b] Ref 70, this data did not keep constant ionic strength, preventing it
from being added to the NIST database; however, it allows for extrapolation of the general trend discussed by Evers et
al.69

Martell et al. suggested a linear relationship between the logK of ligands containing only
negative oxygen atoms and the logK(OH) of the metal ions could be used to predict the affinity of
metal ions for O-donor ligands. This linear relationship was shown to hold true for DFOB,
BAMPTH, and a series of dihydroxamic acids with varying linker chains (CnDHA, III). The
study found that the stability of these complexes with only negative oxygen donors was closely
linked to the affinity of metal ions for the hydroxide ion, leading to difficulty in altering observed
selectivity of naturally occurring siderophores, other than through the introduction of sterically
constrained groups or different donor groups, for example DFO-HOPO. They also reported that
the maximum complex stability with DHA was reached with a chain length of eight methylene
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groups (C8DHA).69 A subsequent study suggested the same relationship existed for the
coordination of Pu(IV) by IX; however, lower standards of experimental design (for example, the
ionic strength was not kept constant) require further study for accurate reporting of the calculated
data. Despite these problems, the reported IX-Pu(IV) stability constant is listed in Table 1,
reflecting an agreement with the original trend studied by Evers et al.69,70

While Martell did not expressly focus on coordination of the f-elements, the synthetic
considerations developed through the synthesis of EDTA-DX and BAMPTH were applied to
subsequent ligand development and study of the f-element complexes. Gopalan et al.71,72 and
Koshti et al.73,74 investigated a new series of cost-effective tetrahydroxamic acid ligand, which
utilized the straightforward aza-Michael reaction to produce a wide variety of ligands, with the
goal of designing Pu(IV) selective ligands for waste extraction. An early ligand design utilized a
meta- or para-substituted xylylenediamine backbone and four propyl hydroxamic acid residues
(IV and V). These ligands were designed with the goal of prearranging hydroxamic acid groups
for optimal octadentate coordination of actinide ions, on an easily tunable backbone which
incorporated amines for water solubility. Th(IV) and Nd(III) were studied as surrogates for
Pu(IV) and Am(III) complexation. Both ligands showed similar affinity for Fe(III) and Th(IV)
and lower affinity for Nd(III). However, V formed slightly stronger complexes with Fe(III) and
Th(IV), most likely due to better preorganization for the formation of strong complexes (Table
2).71 This line of research produced the CYTROX ligand (VII), a cyclam-based ligand with much
potential for actinide selectivity.73 However, the stability of this ligand with a variety of metals
was not studied. In 2000, Santos et al. published a similar ligand with aliphatic hydroxamic acids
on a cyclohexane backbone, cyclohexane-1,2-diyldinitrilotetra(N-methylacetohydroxamic acid)
(H4CDTMAHA, VI) . This ligand was shown to form stronger complexes with Th(IV) and
Fe(III) than the corresponding carboxylate analog, cyclohexane-1,2-diyl-dinitriletetraacetic acid
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(H4CDTA).75 The authors also compared their data to IV. As can be seen in Table 2, VI formed
slightly stronger complexes with Fe(III) and Th(IV) than IV, though they were comparable in
selectivity.71

The aromatic 1,2-HOPO (Figure 1.2) based ligands were more heavily studied. Raymond et
al. published the first Pu(IV)-HOPO crystal structure in 2005. However, this complex utilized the
3,2-HOPO (technically not a hydroxamate) binding moiety on either a TREN or LICAM-type
backbone.76 Previously, Raymond et al. had shown the effectiveness of 1,2-HOPO as a Pu(IV)
extractant from nitric acid solutions.77 In 2011, the same group published the synthesis of a mixed
donor ligand consisting of a TAM (2,3-dihydroxyterephthalamide) backbone and two terminal
HOPO groups (X). This TAM(HOPO)2 ligand was capable of fully coordinating the equatorial
plane of the actinyl (AnO2+/2+) ion in a distorted octadentate geometry. The first two protonation
constants (Table 2) represent the deprotonation of the 1,2-HOPO moieties, followed by the
deprotonation of the TAM group. At pH 3, the 1,2-HOPO groups had fully coordinated with the
uranyl ion.78

Dasaradhi et al. investigated a tetrahydroxamic acid derivative of calixarenes, assuming the
highly preorganized backbone would lend the ligand toward high stability with metal ions (IX)
and provide an effective method for solvent extraction of Pu(IV). Solvent extraction studies using
Th(IV) as a Pu(IV) surrogate, Fe(III), Cu(II) and UO22+ showed IX was capable of extracting
Th(IV) (95-100%) and Fe(III) (98-99%) into a chloroform layer at low pH (1-2) and unable to
extract Cu(II) and UO22+ until higher pH (4-6). The hydroxamate and N-substituted hydroxamate
ligands were slightly more efficient in the extraction of Th(IV) than the corresponding
carboxylate ligand. Despite a lack of selectivity toward Th(IV) in the presence of Fe(III), these
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ligands hold potential as extractants for Th(IV) and Pu(IV) in the presence of UO22+ at low pH (12), typical of reprocessing of nuclear fuel.79
Table 1.2. Stability constant data for ligands IV, V, and VI.
Compound

IV[b]

Reaction

Fe(III)

Nd(III)

Th(IV)

Logβ

Logβ

Logβ

25.54

39.65

32.40

43.16

37.04

45.92

26.28

36.85

[MLH]/[M][L][H]
]/[M][L][H]2

[MLH2

V[b]

[MLH3

]/[M][L][H]3

43.41

[MLH4]/[M][L][H]4

47.43

[MLH]/[M][L][H]
]/[M][L][H]2

40.50

32.78

42.13

]/[M][L][H]3

45.21

37.03

45.18

]/[M][L][H]4

48.70

[MLH2
[MLH3
[MLH4
VI[c]

48.28

[MLH]/[M][L][H]

30.0

[MLH2]/[M][L][H]2

36.23

]/[M][L][H]3

46.39

41.99

]/[M][L][H]4

48.2

46.37

[MLH3
[MLH4

[a] All data reported at 25°C and μ=0.1 KNO3. [b] Ref. 71. [c] Ref. 75. [d] Only stability constants with data for
comparison were reported.

The 1,2-HOPO group has also been incorporated into siderophore analogues, such as DFOHOPO.80 This compound was compared with other multidentate hydroxamic acid ligands, such as
3,4,3-LI(1,2-HOPO) (VIII) and the dihydroxamate DTPA derivative, DTPA-DX.81–83 All of these
ligands were studied for their effectiveness at the removal of Pu-238 and Am-241 after inhalation
and injection contamination routes. These ligands were also directly compared with the
effectiveness of DTPA, the standard treatment for the removal of Pu(IV) and Am(III). VIII has
been shown to be more effective in enhancing the excretion of Pu(IV) after exposure through
injection and inhalation. For the removal of Pu(IV) from the lungs, a repeated dose of 30
μmol/kg-1 of the ligand was capable of lowering the Pu(IV) content in the lungs and total body to
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2% and 4% of the untreated controls, respectively. When treated with the same dosage of DTPA,
the Pu content of the lungs and body were six times and three times more than with VIII.81
Similar results were observed with the treatment of simulated contaminated wounds, 82 and the
early treatment of Pu(IV) and Am(III) contamination (1 hour). 83 The 3,4,3-LI(1,2-HOPO) ligand
has shown high promise as a decorporation agent for the removal of actinides from the body.

Table 1.3. Protonation constants of some polyhydroxamic acid ligands.
Compound

logK101

logK102

logK103

logK104

logK105

logK106

I

9.93[b]

9.00[b]

6.67[b]

3.48[b]

1.6[b]

II

11.1[c]

10.6[c]

7.23[c]

6.05[c]

5.55[c]

1.55[c]

IV

10.18[d]

9.64[d]

8.99[d]

8.17[d]

6.38[d]

5.36[d]

V

10.22[d]

9.60[d]

9.05[d]

8.31[d]

6.40[d]

5.35[d]

VI

9.91[e]

8.88[e]

8.52[e]

7.80[e]

7.56[e]

6.42[e]

VIII

6.64[f]

5.68[f]

5.01[f]

3.87[f]

X

4.91[g][h]

6.56[g][h]

8.7[g][h]

10.2[g][h]

XI

10.04[i]

9.33[i]

8.48[i]

10.04[i]

[a] All data reported at 25°C and μ=0.1 KNO3. [b] Ref. 67. [c] Ref. 68. [d] Ref. 71. [e] Ref. 75 [f] Ref. 85. [g] R=ethylene,
X=1,2-HOPO. [h] Ref. 78. [i] Ref. 50; Ref. 69.

The protonation constants of several polyhydroxamic acid ligands are listed in Table 3. This
data shows how the reported ligands are deprotonated and thus, capable of interacting with metals
at the typical desired pH range of environmental and biological conditions. Further comparison of
the effectiveness of these ligands as f-element chelators is difficult, due to a lack of consistent
data. While some stability constants have been published for these ligands (e.g. Table 2), Fe(III)
and Cu(II) are typically the metals of choice. However, the affinity simple hydroxamic acids
show for the f-elements is similarly demonstrated by the polyhydroxamic acid ligands which have
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been reported. The ligands IV, V, and VI each demonstrate the ability to form strong complexes
with Nd(III) and Th(IV), despite a lack of selectivity over Fe(III).

Figure 1.3. Structures of polyHA small molecules. (I) EDTA-DX,84, (II) EDTPHA,68 (III) DHA,

69

(IV) no

abbreviation provided by the authors,71 (V) no abbreviation provided by the authors,71 (VI) H4CDTMAHA,75
(VII)

CYTROX,73

(VIII)

3,4,3-LI(1,2-HOPO),81–83,85

(IX)

BAMPTH,50,69,70 (XII) no abbreviation provided by the authors.86
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Calix(HYD)4,79

(X)

TAM(HOPO)2,78

(XI)

Polyhydroxamic acid resins

The desire to remove select metals from aqueous environments, along with the need for metal
separations has driven the design of chelating polymers. Vernon published the necessary qualities
of a chelating polymer, which include high capacity, high selectivity and high durability. 87 The
high affinity of hydroxamic acids toward Pu(IV) as seen with siderophores demonstrated a
promising group for functionalization of resins designed toward chelation of the f-elements. The
initial driving force for the development of polymeric hydroxamic acids was to investigate potent
iron(III) chelators for removal from the body and aqueous environments. The initial reported
example was published by Deuel et al in 1954 and utilized a reaction between an acid chloride
and hydroxylamine.88,89

Charles Fetscher published the synthesis of a polyhydroxamic acid-containing radioactive fuel
source from a polyacrylonitrile through the hydrolysis of the amidoxime intermediate. The low
molecular weight of the hydroxamic acid unit allowed for a high chelating capacity and could be
formed into a strong, flexible fabric for use as a radioactive source. Fetscher suggested that the
chelating ability of the polyhydroxamic acid would occur on the surface, allowing for control of
the amount of metal chelation, up to about 50% by weight of the material.95

Petrie, Locke, and Meloan reported the synthesis of a polyhydroxamic acid-functionalized ionexchange resin for metal separations, including V(V), Fe(II), Fe(III), Mo(VI), Ti(IV), Hg(II),
Cu(II), UO22+, and Ca(II). The authors theorized the inclusion of hydroxamic acids would allow
for a gain of advantages over the corresponding resins functionalized with carboxylic acids,
including higher selectivity and better separation of metal ions. A preliminary comparison of the
carboxylic acid and hydroxamic acid funtionalized resins showed an increased elution volume for
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several metals, including Fe(III) (1.5 mL), Cu(II) (0.5-1 mL), UO22+ (1 mL), and Ce(IV) (5 mL),
demonstrating more interaction of certain metals with the hydroxamic acid resin than others.90

The conversion of poly(methyl methacrylate) to the corresponding polyhydroxamic acid
product was reported in N,N‘-dimethylformamide with an 80% conversion yield. This resin was
modeled after the structure of DFOB. The authors determined that the spacing of the hydroxamic
acid units was instrumental in the formation of strong iron(III) chelates, with the optimal spacing
of nine atoms between units.94,96 The DFOB framework was further investigated by Winston et al,
who further investigated the effects of spacing of the hydroxamic acid units and their chelation
efficiency for iron(III). A polymer containing hydroxamic acids side by side, HAP-1 (Figure 1.4),
had a poor performance compared to DFOB due to the inability for units so close to keep iron(III)
chelated in an octahedral geometry. However, the use of β-alanine in place of alanine allowed for
11-atom spacing between the units, HAP-II (Figure 1.4). The larger spacing allowed for similar
chelating efficiency as DFOB. A smaller, more crowded polymer, HAP-III (Figure 1.4), showed a
much lower affinity for Fe(III) consistent with the lack of the 8-9 atom spacers.97 These results
further confirm the importance of spacing between hydroxamic acid groups for metal chelation
that was previously reported by Evers et al.69

Figure 1.4. Structures of DFOB-inspired polyhydroxamic acid resins with varying spacing between hydroxamic
acid units.97
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The polymerization of an acrylonitrile-divinylbenzene copolymer, followed by hydrolysis and
subsequent reaction of the polyamide with hydroxylamine, led to a promising polyhydroxamic
acid ion-exchange resin which was investigated for removal of uranium from seawater. The
authors were able to remove Fe(III) and U(VI) from seawater with 97-99% efficiency.98 Selective
absorption and desorption of metals through strict control of the pH allowed for the separation of
U(VI) from a variety of trace metals utilizing a PHA resin bead system. The authors found the
optimum pH for U(VI) adsorption to be 4 with a U(VI) capacity of 2.9 mmol/g, however at the
relevant pH of seawater, 7.8, the resin had a capacity of 0.9 mmol/g. They were also able to
discern that a contact time of 10-20 minutes between seawater samples and the resin was
necessary for >50% extraction of the U(VI).96

Phillips and Fritz compared the efficiency of resins functionalized by hydroxamic acid, Nmethylhydroxamic acid, and N-phenylhydroxamic acid with the extraction of nineteen metal ions
as a function of pH and found the N-methyl resin had the highest metal capacity. This resin was
shown to be effective at the removal of U(VI) (99-101%) from synthetic seawater samples at pH
7-8. They were also able to separate Th(IV) from U(VI) through the elution of the former by 3M
HCl and the latter by 3M HCl and the addition of 0.1M oxalic acid.99

More recently, Agrawal and coworkers have explored a series of N-substituted
polyacryloylhydroxamic acid ion-exchange resins (including N-phenyl, N-p-tolyl, N-m-tolyl, N-otolyl, N-p-chlorophenyl, N-m-chlorophenyl, N-p-bromophenyl and N-p-iodophenyl) which were
synthesized from a reaction of polyacryloyl chloride and N-arylhydroxylamines to give 80-95%
yields and strong coordination of divalent metals (Pb(II), Cu(II), Ni(II)). 91,92 Subsequent
development of a synthetic route toward poly(β-sytryl)hydroxamic acids led to the study of a
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series of new poly(styrene)hydroxamic acid resins (A and B, Figure 1.5) and their use in U(VI)
and Ln(III) determination in rock and seawater samples (1-10 ppm).93,100,101

Figure 1.5. Structures of (A) poly(β-styrene)hydroxamic acid100 and (B) poly(styrene-p-hydroxamic acid)
resins.101

Mendez et al attached N-phenylhydroxamic acid to poly(styrene-co-maleic acid) cross-linked
with divinylbenzene and studied the effects on extraction of ten metals, including Fe(III), Zn(II),
and U(VI). The maximum sorption of U(VI) occurred at pH 4.5 with a capacity of 0.13 mmol/g
resin and 50% maximum sorption after three minutes exposure time.102 Rahman and coworkers
developed a polyhydroxamic acid resin with a poly(methyl acrylate) grafted on a sago starch
backbone and studied the chelation behavior with the trivalent lanthanides. The resin had a
capacity for La(III) of 2.3 mmol/g resin at an optimal pH of 6. The resin selectivity toward the
lanthanide metals followed the trend La(III) > Dy(III) > Pr(III) > Ce(III) > Nd(III) > Gd(III) >
Eu(III) > Tb(III).103,104

The chelation effect of poly(amidoxime-hydroxamic acid) and poly(N-methyl amidoxime-Nmethyl hydroxamic acid) resins toward the trivalent lanthanides was studied by Alakhras and
coworkers. The authors noted that 90% of the metal uptake occurred after 2-3 hours and the resin
capacity increased with decreasing ionic radii (Tb(III) > Gd(III) > Sm(III) > Nd(III) > La(III)), in
agreement with previous literature involving simple hydroxamic acids and Ln(III), however the
trend was opposite of that published by Rahman et al.103,105 The authors did note that the inclusion
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of the N-methyl group appeared to be beneficial to metal uptake, possibly due to higher stability
constants of the hydroxamic acid-metal complexes.105

Polyhydroxamic acid resins show promise for the chelation of f-elements in aqueous systems.
Although most studies have focused on the uptake of uranium from seawater or nuclear waste
environments, these resins also hold potential as decorporation agents. Each system is dependent
on the separation of different metals and different pH ranges, further complicating the overall
comparison of work due to the lack of consistent studies and stability constants of the hydroxamic
acid groups.

Conclusion

The research presented here covers a broad spectrum of the development of polyhydroxamic
acid ligands and their potential as f-element chelators. Early hydroxamate chemistry involved
several studies of the use of monohydroxamic acids for actinide chelation,28,106,107 however the
use of polyhydroxamic acid ligands grew in popularity with the discovery of siderophores such as
ferrichrome and desferrioxamine due to the similarities of Fe(III) and Pu(IV) chemistries.1,2,18

Early attempts of siderophore analogs, such as DFOM, provided little advantage over
traditional ligands (e.g. DTPA) when applied to Pu(IV) decorporation studies, due to a lack of
selectivity and degradation in vivo.58–60 The deviation from siderophore backbones and the
consequent development of polyhydroxamic acid ligands with a variety of backbones has led to a
variety of promising polydentate ligands for the coordination of f-elements.

Research into polyhydroxamic acid resins has also recently come to the limelight. Early work
with these resins was hindered by the incomplete conversion to the desired hydroxamic acid unit
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and the consequent by-products poisoning the chelate efficiency of the resin.88–90,94,96 However,
new methods have been developed utilizing acrylamides and amidoxime-hydroxamic acid
combinations, providing higher conversion yields and promising methods for Ln(III)-Ln(III),
Ln(III)-An(IV), and Ln(III)-transition metal separations.91,100,101 Current efforts have focused on
the development of resins for removal of Pu(IV) from carbonate solutions, such as those
produced from the alkali washes of the PUREX process.108

While the field has far to go, the development of polyhydroxamic acids has produced many
promising ligands for coordination of the f-elements. These ligands have potential for use in a
variety of fields, including environmental remediation, biological decorporation and nuclear
waste reprocessing.

Note: This chapter reflects an article accepted to Chemistry-A European Journal (July 2018).

This chapter discusses a narrow focus of f-element ligand design, hydroxamic acid ligands.
However, it serves as an introduction to the overall goal of this dissertation, the development of
highly selective ligands for the f-elements with the ability to form stable metal complexes in
competitive environments. Three approaches toward this goal were taken, including
azamacrocycles, cyclopeptoids and polyhydroxamate EDTA derivatives. Each approach utilized
the same considerations discussed above for the design of f-element ligands, ligand topology,
multidentate binding capability, and strong coordination of the target metals.
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CHAPTER TWO
AZAMACROCYCLIC LIGANDS FOR SELECTIVE ACTINYL COORDINATION
2.1 Introduction
Actinides (An) are known to exist in a wide variety of oxidation states, from An2+ to An7+. The
early actinides, Th-Pu, are more similar to the early transition metals than the later actinides,
marked by higher stable oxidation states and the formation of covalent bonds with ligands. The
late actinides, Am-Lr, exist primarily in a stable An3+ oxidation state and form ionic bonds,
similar to the lanthanides.1,2 The 5f orbitals are more available for bond interactions than the 4f
orbitals due to the presence of a radial node that places the electron density further from the
nucleus and less “buried” by other orbitals.2

Figure 2.1: General actinyl ion structures

Uranium, neptunium, plutonium and americium exist as stable actinyl ions, where the metal
ion forms double bonds to two oxygen atoms in a near-linear structure, shown in Figure 2.1. In
aqueous solutions, these complexes form through the hydrolysis of aquo ligands. These unique
actinide ions provide excellent targets for ligand design. The UO22+ ion is the most stable form of
uranium in aqueous solutions and is often targeted in the design of uranium-specific ligands.3,4
Most reported uranyl-binding ligands only interact with the equatorial plane, with few examples
of interaction with the oxygen atoms.5–7 Figure 2.2 is representative of the general design
followed for actinide ligands. It is comprised of a bulky, organic macrocyclic molecule with hard
donors that interact with the uranium ion in the center of the macrocycle.8 Despite the formation
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of stable uranium complexes with the aforementioned ligands, actinide selectivity remains an
issue in complex environments.9
The radioactive properties of actinides have led to many industrial needs for actinide-specific
ligands. The mitigation of the continuously increasing volume of nuclear waste is at the forefront
of actinide research.2,3 Nuclear waste is comprised of three types of radioactive waste: low,
intermediate, and high level. High level waste, accounting for 95% of the radioactivity of nuclear
waste, consists of depleted uranium (96%), plutonium (1%), and fission products, such as
lanthanides (3%).10 Reprocessing of the high level waste not only decreases the amount of
radiation present, but also allows for the recycling of the uranium and plutonium collected. The
most widely commercially used method for reprocessing nuclear waste is the Plutonium and
Uranium Extraction (PUREX) method. This solvent extraction method was designed during the
Manhattan Project and has experienced only minor modifications since, focused on decreasing
the amount of additional waste produced and preventing the production of pure plutonium.2

Figure 2.2: Top and side views of an expanded-porphorin uranyl complex 8
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The increased demand for nuclear power has also increased the demand for uranium fuel. The
current demand for uranium ore is 67 kton/year and is expected to double by 2030. 10 Seawater
contains four gigatons of uranium, 1000 times more than the uranium in land.11–13 This source is
mostly untapped due to the low concentration of uranium (3 ppb) in comparison to other
competitive metal ions (Na+, K+, Ca2+, Mg2+) and the formation of stable carbonate-uranium
species. Other important areas of actinide-ligand research are the need for environmental
remediation of actinides after spills or use of nuclear weapons and chelation therapy following
actinide exposure.9
Crown ethers and aza-crown ethers have been shown to form stable complexes with the uranyl
ion. The most well characterized complex is that of UO22+ and 18-crown-6. A crystal structure of
this complex has been solved and shows the macrocycle interacting with the uranium ion, which
sits in the middle of the ligand.14–16 However, other metals ions, such as potassium, could easily
displace the uranyl ion. We hypothesize that selectivity and the stability of the actinide complex
can be increased by utilizing the crown ether backbone and incorporating sidearms that can
interact with the two actinyl oxygen atoms. Although there are no current examples of ligands
that can bind both actinyl oxygen atoms, modest gains in selectivity have been observed using
ligands designed to bind one actinyl oxygen.17

Figure 2.3: TEG-based ligand structure of L1, L2, and L3.
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This chapter discusses the design and characterization of a macrocyclic diazacrown ether
ligand for coordination of the uranyl ion. The original goal of this project was to synthesize a
series of ligands incorporating the diazacrown ether backbone and amine sidearms of varying
lengths for selective control of the ligand topology. The final goal was to study the solution
thermodynamics of the uranyl complexes of these ligands to gain a better understanding of the
necessary structural restraints for high selectivity and coordination of the uranyl ion. However, as
will be discussed, problems arose from the flexibility of the diazacrown ether backbone which
prevented this project from progressing past its infancy.

Scheme 2.1: The synthesis route for diaza-crown ether ligands containing diamine sidearms. Triethylene glycol
is activated through tosylation and then cyclized through a substitution reaction with the diamine sidearms. An
alternate route is shown in a box where the tosyl group is replaced by iodine before cyclization.

2.2 Results and Discussion
Ligand Synthesis
The initial synthetic route was focused on allowing for straightforward manipulation of the
backbone size as well as the sidearms. Due to this requirement, we began by activating
triethylene glycol (TEG) through tosylation. This reaction initially produced a low yield, due to
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the necessity of multiple columns for purification. However, using potassium hydroxide in place
of the pyridine allowed for purification through recrystallization due to easier removal of excess
base, which could potentially increase yield and decrease the time required for purification.18–20
The tosyl group was then displaced in a 2+2 cyclization reaction with a Boc-protected diamine, as
shown in Scheme 2.1. The Boc-protecting group was thermally unstable above 80°C, which
required the change from dioxane to acetonitrile as our solvent. It also increased the time of
reaction from four days to over two weeks. Column chromatography was used for purification of
the final ligand. Once a pure product was obtained, the Boc-protecting groups were removed in
80% trifluoroacetic acid/methanol.
An alternative route to avoid the presence of the tosyl counterion was attempted by
substituting iodine for the toluenesulfonyl groups (iii, Scheme 2.1). This reaction proceeded
quickly and required minor purification. The diiodinated product was not stable, so it was quickly
used in the cyclization step. However, the final cyclized product was not isolated through this
method. It is possible that the tosyl counterion is instrumental in the cyclization step through a
template effect.
The top route in Scheme 2.1 was used to successfully synthesize L1 and L2 (Figure 2.3). Both
syntheses were low yield (<10%). Only L1 was subsequently used in complexation studies with
uranyl nitrate.

Scheme 2.2: Routes toward mono-N-Boc protection of m-xylylenediamine.
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The synthesis of L3 required a preliminary mono-Boc protection of the m-xylylenediamine
starting material, before moving forward with the ligand synthesis in Scheme 2.1. Two methods
of N-Bocylation were attempted. Route 1 (A, Scheme 2.2) followed a literature procedure for the
esterification of phenyl chloroformate with tert-butanol.21 This product was isolated through
extraction to give 50% yield. However, the subsequent N-Boc protection of m-xylylenediamine
did not lead to a clean product. An alternative literature produce utilizing Boc anhydride was
attempted (B, Scheme 2.2).22 The mono-Boc protected product was purified through column
chromatography before being used in the synthesis of L3 (Figure 2.3). The route in Scheme 2.1
was used for the synthesis of L3. Unfortunately, L3 was not successfully isolated.
Ligand Characterization
The ligands were characterized through MALDI-TOF (Figure 2.4), 1H NMR and 13C NMR.
The MALDI-TOF spectra of the ditosylated TEG backbone, Boc-protected L1, and deprotected L1
are shown in Figure 2.4. The 1H NMR and 13C NMR both show a pure product with tosylate and
trifluoroacetic acid counterions. In the 1H NMR, a tosylate counterion can be assigned to the
singlet at 2.2 ppm as well as the aromatic peaks (7.2, 7.3, 7.4, 7.6 ppm). The remaining peaks
correspond to the macrocyclic product. The

13

C NMR not only shows evidence of a tosylate

counterion (19, 125, 129, 139 and 142 ppm), but also the presence of a trifluoroacetic acid
counterion from the deprotection of the Boc-protecting group (112-119, 162 ppm). The remaining
seven peaks correspond to the cyclic macrocycle. The L1-uranyl complexation products were
characterized with ATR-FTIR and UV-vis (below).
L2 was never fully isolated. MALDI of the crude reaction showed the presence of the desired
product, however, once extraction or a column was performed, the product peak disappeared. It is
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possible that degradation of the Boc-protecting groups occurred during purification of the crude
reaction.

Figure 2.4: MALDI-TOF of crown-ether ligand synthesis using HCCA/TFA matrix

Ligand-Actinide Complexation
Complexation with uranyl nitrate hexahydrate was initially carried out at 1 mmol scale. Due to
the nature of the metals being studied (U(VI), Np(V), Pu(V)), validation of the synthesis was
necessary before moving to potentially larger scales. A second complexation at 60 mmol scale
was carried out to validate complexation at a higher concentration. In both cases an equimolar
solution of L1 and uranyl nitrate hexahydrate in Milli-Q water was heated at 80°C for 120 hours.
No further purification was performed prior to characterization.
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Figure 2.5: ATR-FTIR spectra of uranyl-L3 complex (red, 0.3 M), uranyl nitrate (blue, 0.3 M), and L3 (green,
0.01 M).

Attenuated total reflection-infrared spectroscopy (ATR-FTIR)
Samples were spotted on a diamond crystal and evaporated in situ with nitrogen. Each
spectrum was then collected in triplicate and averaged. Spectra were collected for: 0.3 M uranyl
nitrate stock, 0.3 M UO22+-ligand, and 0.01 M ligand, all dried from Milli-Q water. A diluted
sample of the UO22+-ligand (0.01 M) was also run to further investigate the presence of changes
in the spectra at lower concentrations. The spectra are shown in Figure 2.5.
The peaks at 940 cm-1 and 800 cm-1 are indicative of the uranyl antisymmetric and symmetric
stretches, respectively. Upon complexation, there was a notable shift in both peaks, giving
evidence toward a change in the ligand geometry of the uranyl ion. Further evidence toward this
change is seen in the two broad peaks at 1480 cm-1 and 1265 cm-1, which are characteristic of the
nitrate groups complexed with uranyl. Complexation leads to a drastic decrease of these peaks,
consistent with the loss of these nitrates. However, studies of the various hydrates of uranyl
nitrate (di-, tri-, and hexa-) have shown that the hexahydrate does not typically produce these
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nitrate peaks and appears more like an ionic nitrate ion. Our peaks are more similar to those seen
with the uranyl trihydrate compound, suggesting a possible dehydration of the sample occurred
during drying.23,24 Both trends were noted for both concentrations (0.01 M and 0.3 M), giving
more evidence toward a successful ligand exchange occurring.
Ultraviolet-visible spectroscopy (UV-vis)
Samples were diluted to 60 mM and UV-vis spectra were collected in triplicate in matching
quartz cuvettes on a Cary-300 spectrometer. The spectrum (Figure 2.6) shows the uranyl nitrate
stock solution as well as the uranyl-ligand complex. The characteristic peak pattern of the uranyl
ion experiences a change in absorbance as well as a slight blue-shift in wavelength upon
complexation, again consistent with a change in the uranyl’s ligand environment in the presence
of our ligand. The addition of a strong ligand, such as a carbonate or amine, to the uranyl ion has
been shown to induce an increase in absorption. Meanwhile, hydrolysis products produce a low
absorbance, so the change in the spectrum suggests no hydrolysis of the uranyl ion occurred.25

Figure 2.6: UV-vis spectrum of uranyl-ligand complex.
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2.3 Conclusion
L1 and L2 were both successfully synthesized, however only L1 was purified and subsequently
used. The synthetic route that was used was inefficient and produced an overall yield <10%.
Attempts of utilizing a better leaving group than tosylate (iii, Scheme 2.1) gave evidence that a
template effect with the tosyl counterion is necessary for the final cyclization step of the ligand
synthesis (ii, Scheme 2.1). Extensive purification of each step drastically diminished the yields of
the reactions. Despite this, L1 was isolated and used in a complexation study with uranyl nitrate.
Initial evidence suggested the successful complexation of uranyl with L1. A shift in the
symmetric and antisymmetric FTIR peaks for the UO22+ ion as well as the loss of the nitrate peaks
suggested the formation of a complex. UV-vis results also suggested the formation of a uranyl
complex due to the slight shift of peaks. Nierlich and coworkers showed the coordination of the
uranyl ion by the parent azamacrocycle in organic solvents when a non-coordinating triflate
counterion.15 However, the presence of the more strongly coordinating nitrate anion prevents the
inclusion of the uranyl ion into 18-crown-6 (instead the uranyl was present as a counterion,
uncoordinated by the macrocycle).26 Consequently, although FTIR and UV-vis were consistent
with at least some interaction of L1 with uranyl in water, it was decided that an alternative, more
strongly-coordinating macrocycle, could provide a better framework for a second-generation
approach.
Additionally, preliminary computational work showed the preference of the 18-diazacrown-6
backbone for collapsing inward, which would prevent the coordination of a metal ion. With this
information in mind, reviewing the FTIR and UV-vis data suggests no more than partial change
of the coordination environment around the uranyl ion. Specifically, it is possible that the shifts
seen in FTIR are only due to dehydration of the samples during sample preparation, which
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involved the drying of the samples with nitrogen and the UV-vis data could be showing the
hydrolysis of the uranyl ion rather than complex formation.
2.4 Future Directions
The ultimate goal of this project was to determine the structural requirements for the
coordination of both uranyl oxo-atoms by studying the solution thermodynamics of three
azamacrocyclic-based ligands. The synthesis of L1 successfully provided a ligand for
complexation with uranyl. However, literature precedence, preliminary computational modeling
and the FTIR and UV-vis data suggest no formation of a complex.
Initial computational geometry optimization by Dr. Shuller-Nickles of only the macrocyclic
portion of the ligand backbone showed a possible preference of the backbone for geometries not
conducive to metal coordination. A possible way to combat this issue would be the incorporation
of rigidity into the backbone, creating a preorganized structure designed for metal coordination.
This could be achieved by integrating 2,3-dihydroxyterepthalic acid, a well-known actinide
ligand27. The incorporation of the terepthalic acid would be performed using NHS-activation of
the

carboxylic

acids,

and

subsequent

reaction

with

a

corresponding

amine

(e.g.

diethylenetriamine). The preorganization of the backbone toward cyclization could also
potentially allow for higher reaction yields by circumventing the high energy of cyclization.
To further increase selectivity for the uranyl ion, rigidified sidearms can be incorporated into
the ligand. This can be done through the use of xylylenediamine rather than the alkyl diamine
sidearms. Reducing the number of free, rotatable bonds in the sidearm would decrease the
entropy loss upon binding of the uranyl oxygen atoms. This strategy was employed with the
TEG-based ligands (L3). Unfortunately, mono-N-Boc protection of m-xylylenediamine was not
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successful. However, further investigation into this reaction could lead to a new strategy that
would allow for incorporation into the diazacrown backbone.
The initial attempts to coordinate L1 with uranyl nitrate proved unsuccessful due to the
flexibility of the diazacrown backbone and its preference for collapse in solution. This conclusion
led to the termination of the development of L1, L2 and L3. However, understanding the issues
with the original 18-diazacrown-6 backbone provides some evidence toward the ultimate goal of
investigating the structural requirements for the full coordination of the uranyl ion. Future
investigations into this project should incorporate this finding through implementation of more
rigidity into the backbone.
2.5 Materials and Methods
Chemicals. Triethylene glycol, pyridine, and tosyl chloride were obtained from Alfa Aesar.
Dichloromethane, acetonitrile, dichloromethane, di-tert-butyl dicarbonate, and sodium
bicarbonate were received from BDH. TFA was obtained from Oakwood Chemicals. Tert-butylN-(2-aminoethyl)carbamate and tert-butyl-N-(2-aminobutyl)carbamate were obtained from AK
Scientific. 1,4-dioxane was obtained from Beantown Chemicals. α-Cyano-4-hydroxycinnamic
acid and m-xylylenediamine were obtained from Acros. All chemicals were used without further
purification.
General. 1H NMR and 13C NMR were collected on a Bruker 500 MHz FT-NMR spectrometer
using deuterated solvents (CDCl3, D2O, DMSO). All NMR data is reported in ppm. MALDI-TOF
data was collected on a Bruker Onmiflex MALDI-TOF mass spectrometer using a stainless steel
plate and HCCA matrix in acetone/formic acid. UV-vis spectra were collected with a quartz
cuvette and a Cary-300 spectrometer.
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General Procedure for Deprotection of Boc groups: Ligands were stirred overnight in a mixture
of 80% TFA/MeOH. The solvent was removed in vacuo to give quantitative yield.

Synthesis of 1,2-ethanediylbis(oxy-2,1-ethanedyl) bis(4-methylbenzenesulfonate) (2): Triethylene
glycol (4.077 g, 27.1 mmol) was cooled to 0°C in dichloromethane (25 mL). Pyridine (3 eq, 81.3
mmol) was slowly added. Last, tosyl chloride (2.2 eq, 59.6 mmol) was added and the reaction
immediately changed from colorless to yellow. After the tosyl chloride addition, the reaction was
removed from ice and stirred at room temperature for 18 hours. The product was cooled to 0°C
and purified by column chromatography (0-10% MeOH/DCM). The product was isolated as a
white powder (35% yield), (Rf: 0.575, 2% MeOH/DCM), 1H NMR (500 MHz, DMSO): 7.78-7.77
δ (d, J = 8.23 Hz, 2H), 7.47-7.46 δ (d, J = 8.23, 2H), 3.38 δ (s, 2H), 2.41 δ (s, 3H), 13C NMR (500
MHz, DMSO): 144.9 δ, 132.4 δ, 130.1 δ, 127.6 δ, 69.9 δ, 69.6 δ, 67.9 δ, 21.1 δ, m/z: 458.2
(calc), 481.4 (+ Na+, obsd), 497.3 (+ K+, obsd).

Synthesis of (4): (2) (5.84 g, 12.7 mmol) was dissolved in acetonitrile, then 2-methyl-2popanyl(4-aminobutyl)carbamate (1 eq, 12.7 mmol) and sodium bicarbonate (2 eq, 25.4 mmol)
were added and the reaction was refluxed for 120 hours without exceeding 80°C to prevent
deprotection of the Boc-group. The solvent was removed in vacuo and the product was purified
by column chromatography (0-20% MeOH/DCM). The product was isolated as a white solid
(26% yield), 1H NMR (500 MHz, DMSO): 7.53-7.51 δ (d, J = 8.14 Hz, 10H), 7.15-7.14 δ (d, J =
8.14, 10H), 3.72-3.67 δ (m, 2H), 3.58-3.57 δ (m, 2H), 3.42 δ (s, 14H), m/z: 605.1 (calc), 605.8 (+
H+, obsd), 628.3 (+ Na+). This product was deprotected using the General procedure for
deprotection of Boc groups.

L1 (1,10-dibutane diamine-1,10-diaza-18-crown-6): The product was an oil. 1H NMR (500 MHz,
D2O): 7.62-7.61 δ (d, J = 8.35 Hz, 3H), 7.31-7.29 δ (d, J = 8.35 Hz, 3H), 3.81-3.77 δ (m, 9H),
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3.67 δ (s, 10H), 3.41-3.39 δ (m, 8H), 3.23-3.20 δ (t, J = 7.99 Hz, 4H) 2.99-2.96 δ (t, J = 7.61 Hz,
4H), 2.32 δ (s, 4H), 1.75-1.66 δ (m, 8H), 13C NMR (500 MHz, D2O): 163.2 δ, 162.9 δ, 162.3 δ,
142.6 δ, 139.8 δ, 129.6 δ, 125.5 δ, 119.9 δ, 117.6 δ, 115.3 δ, 112.9 δ, 70.9 δ, 70.0 δ, 69.9 δ, 69.87
δ, 69.83 δ, 69.8 δ, 69.6 δ, 64.4 δ, 64.2 δ, 63.9 δ, 53.5 δ, 53.1 δ, 52.9 δ, 43.6 δ, 38.9 δ, 24.0 δ, 20.6
δ, 20.4 δ, 19.8, m/z: 405.1 (calc), 405.8 (+ H+, obsd), 428 (+ Na+, obsd).

L2 (1,10-diethane diamine-1,10-diaza-18-crown-6): The same method was used as for L1. The
product was an oil.
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CHAPTER THREE

CYCLIC PEPTOIDS AS SIDEROPHORE ANALOGUES FOR TETRAVALENT
ACTINIDE COORDINATION

3.1 Introduction

Tetravalent actinides form stable, insoluble hydroxides which pose a major environmental
hazard. The preference for these ions to hydrolyze into the insoluble hydroxides can lead to
accumulation of radioactivity in unwanted areas.1–3 Additionally, the similar chemistries of
Fe(III) and Pu(IV) make Pu(IV) an exceptional target for biological Fe(III) chelators, such as
transferrin, allowing for the internal transportation and amassing of this toxic metal.4–8 The design
of ligands to target the tetravalent actinides is heavily influenced by naturally-occurring Fe(III)
chelators known as siderophores. These small molecules are produced by bacteria and fungi to
aid the solubilization and transportation of Fe(III) from soil into their biological systems. 9–12 The
coordination of the actinides by the trishydroxamate siderophore desferrioxamine (DFO)13–16 and
the triscatecholate siderophore enterobactin17 have demonstrated the extraordinary potential that
the siderophore framework has for coordination of these metals.

Peptoids, N-substituted glycine oligomers, hold advantages over peptide analogues due to
synthetic benefits gained from the N-substituted glycine monomers they are comprised of. The
movement of the sidearm from the α-carbon to the nitrogen allows for more flexibility of the
glycine backbone and consequently, more straightforward cyclization of the backbone. 18–21
Additonally, peptoid synthesis is not limited to the natural amino acids, allowing for more
customization through the use of any primary amine as the source of the peptoid side chain.18,22
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For these reasons, cyclic peptoids offer a synthetic route toward peptidomimetics of peptide
siderophores for tetravalent actinide coordination.

Figure 3.1: Macrocyclic ligands interacting with various metal ions (a-c) and different configurations of the
chelating hydroxamate utilized in ferrichrome analogs (d-f). The pink box highlights the macrocyclic backbone.
a) Interaction between ferrichrome and iron(III),23 b) cartoon showing interaction between cyclic hexapeptoid
backbone carbyonyls and sodium, c) illustration of potential coordination by a peptoid hydroxamate
siderophore, d) ferrichrome hydroxamate moiety, f) desmethylhydroxamate ferrichrome moiety, f)
retrohydroxamate

Two siderophores, ferrichrome (Figure 3.1)23 and enterobactin, are comprised of a cyclic
backbone and three metal-chelating arms, including three hydroxamic acid or catechol moieties,
respectively. Alternatively, most literature concerning metal-peptoid complexation shows weak
interaction between the carbonyls in the cyclic backbone with Group 1 or II metals. 20,24,25 Figure
3.1 shows the coordination mode this work hopes to effect by combining the cyclic-peptoid
backbone with sidearms similar to those found in siderophores. Since most metal-peptoid
interactions occur via weak carbonyl interactions25 or sidechains in a helical structure26, this work
represents a new approach toward peptoid coordination chemistry. As seen in Figure 3.1, by
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incorporating metal chelators into the sidearms, the coordination of metals in a similar fashion to
the highly efficacious design of siderophores such as ferrichrome is possible.

Peptoids
Peptoids (N-substituted glycine oligomers) were first reported in 1992.18,22 The advantages of
peptoids stem from the structural difference between peptoids and peptides, where the side chain
has been moved from the alpha carbon to the nitrogen. The sidechains therefore arise from
primary amines used in the synthesis rather than requiring asymmetric synthesis to make new
amino acids.18 The modular synthesis allows for each residue to be installed separately and a wide
variety of sidechains to be incorporated.27 Peptoids are also resistant to proteolytic degradation28
and flexible, allowing for simple cyclization and distinct secondary structure formation.21,29,30
They have been investigated for many applications, including antimicrobial agents,31,32 phasetransfer catalysts,33 MRI contrast agents,34 and other peptidomimetic applications.20,22,35–38

Figure 3.2. Structure of (left) peptoid and (right) peptide dimer.

Peptoids can be synthesized similarly to peptides using Fmoc-protected N-substituted glycine
monomersFmoc,39 although are more commonly synthesized using the submonomer synthesis as
described later in the chapter. The macrocyclization of peptoids has been shown to provide rigid,
distinct secondary structures capable of selectivity toward target molecules.21,24,40 Peptoids exhibit
a rapid cis-trans tertiary amide conversion which allows for cyclization without high-dilution
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conditions.21,40 A variety of side chains can be introduced into the peptoid-backbone through the
use of primary amines in the submonomer synthesis. This allows for the introduction of
properties, such as metal selectivity, e.g. hydroxamate and catecholate units.

Siderophores

In 1952, Neilands, et al reported the isolation of a non-protein crystalline compound from the
rust fungus, Ustilago sphaerogena, which had been grown in a yeast-containing medium in an
attempt to study the increased cytochrome-c production. This compound was shown to contain
iron through the use of UV-vis and was subsequently labeled ferrichrome.9,41,42 In the same year,
Hesseltine et al reported the isolation of a red, crystalline, biologically active non-protein
compound from the fungi, Pilobolus, while studying new growth media. This compound was also
shown to contain iron, but was labeled coprogen.43,44 Over a decade later, in 1967 a third
compound of similar properties was isolated and shown to break down into the monohydroxamic
acid fusarinine. This was labeled fusagen, later acknowledged as part of the fusarinine
siderophore family.45,46

Fungi predominately produce hydroxamic acid-containing siderophores, which fall into three
categories, fusarinine, coprogen, and ferrichrome. The fusarinine family includes both linear and
cyclic mono-, di- and trimers of acylated ornithinine groups. Coprogens contain di- or
trihydroxamic acids composed of trans-fusarinine subunits. Ferrichromes, the most common
fungal siderophore, are nearly all cyclic, trishydroxamic acid, hexapeptides derived from N5hydroxyornithine.10 The commonalities among the fungal siderophores include the incorporation
of hydroxamic acids and the derivation from L-ornithine. The only polyhydroxamic acid
siderophores derived from N6-hydroxylysine are aerobactins, mycobactins, and exochelins.47
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The hydroxamic acid moieties form stable, five-membered rings with the Fe(III) ion through
primarily electrostatic interactions. The L-ornithine units of siderophores allow for a large
distance to exist between the multiple hydroxamic acid residues. For this reason, despite being
attached to one molecule, the siderophore hydroxamic acids do not benefit from the chelate
effect.48–50 Instead, their Fe(III) complex stability is due to the concentration effect, where they
are able to more effectively bind Fe(III) at lower concentrations than monohydroxamic acids. 10
This is due to the need for fewer moles of the compound to be present for a higher ratio of
complex:uncomplexed metal ions. This same lack of chelate effect is noted in the
desferrioxamine B system.51 The lack of chelate effect was later confirmed by Yoshida et al with
their work with the synthetic ferrichrome analogue, BAMTPH.52

In general, bacterial siderophores have been investigated for medicinal applications, such as
antitumor10,53, antimalarial,54,55 and antibiotic agents56–58. Desferrioxamine (DFO) has been the
most heavily studied siderophore for these applications. Similar to the fungal siderophores,
DFOB, a linear bacterial siderophore produced by Streptomyces pilosus, contains hydroxamic
acid moieties, which increase the effectiveness as an iron chelator.59 Desferal, desferrioxamine
mesylate, was approved by the FDA in the mid-20th century for the treatment of iron overload and
thalassemia. Desferal helps solubilize biological iron(III), which is then excreted from the body.
However, Desferal is not orally active and requires prolonged intravenous delivery.55,59–61
Desferrioxamine is cleared from the body with a t1/2 of 5-10 minutes. Therefore, for necessary
iron excretion levels to be maintained, the intravenous delivery must be 8-12 h/day and 5-7
d/week.59,61

An additional application of DFO was investigated due to its potential antioxidant properties.
Reactive oxygen species (ROS) are created through the oxidation of Fe(II) to Fe(III) by O2- or
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H2O2 in the body. These ROS can lead to DNA damage and subsequent diseases. The ratelimiting step for this catalytic ROS production in vivo is the reduction of Fe(III) back to Fe(II),
and DFO has been investigated for its ability to prevent Fe(III) from being reduced. The DFO
fully protects the Fe(III) core from reduction by forming a octahedral binding pocket.62 EDTA
differs because it is too small to fully protect the Fe(III) core, allowing one labile water molecule
to interact with the Fe(III). This water molecule is capable of exchanging with oxygen or
hydrogen peroxide, leading to possible radical formation.55,59 Additionally, the possible synthesis
of an enzyme-damaging nitroxide radical upon reduction has been investigated for its potential
for some of the unwanted side effects caused by long-term Desferal usage.62 DFO has also been
used to treat Al(III) overload and with 68Ga(III) as an agent for radiography.63

The linear DFOB is a well-studied, strong chelator of Fe(III). However, the cyclic DFOE has
been shown to form a more stable complex with Fe(III). As the complex forms, the three
hydroxamate groups must form stable five-membered rings with the Fe(III) ion. The
preorganization of the cyclic DFOE allows for this to happen with a lower change in entropy
relative to linear DFOB, allowing for a more stable complex to form.51 The cyclic siderophores,
such as DFOE and ferrichrome, offer more opportunities for highly stable metal complexes.

Ferrichrome binds Fe(III) with a stability constant ~10x that of EDTA and is highly selective
for the Fe(III) ion. In the presence of Cu(II) and Zn(II), the iron complex remains stable.9 The
acid hydrolysis of the complex leads to desorption of the iron ion and loss of the characteristic red
complex color. However, the complex is easily reformed at higher pH and remains stable up to
pH 11-12. The hydroxamic acid residues were not positively identified for several years due to a
lack of literature focus on that functional group. The well-known purple color produced by
Fe(III)-monohydroxamic acid complexes is not replicated by Fe(III)-ferrichrome complexes.
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Instead, a yellow color is produced, indicative of a 3:1 ligand:metal complex. This is due to the
presence of three hydroxamic acid residues in the ferrichrome structure.64
Ferrichromes are produced by nearly all known families of fungi. 10 Synthetic analogs of
ferrichrome have been heavily studied for possible medicinal applications.65–68 For example,
retrohydroxamate ferrichrome (side chain reversed from typical, as shown in Figure 3.1d, to an
inverted configuration, as shown in Figure 3.1f) was synthesized and shown to have little effect
on Fe(III) binding affinity, but desferriretrohydroxamate ferrichrome led to the complete loss of
iron transport and uptake by the cells, suggesting the necessity of structural recognition of the
ferrichrome-Fe(III) complex for cellular iron uptake.23,65,69–72 The difficulty of cyclizing peptides
has hindered the synthesis of peptide analogs. In 1982, only rhodotorulic acid,73 dimerum acid
and ferrichrome74 had been fully synthesized.47 In contrast to the handful of peptide analogs, a
large spectrum of non-peptide analogs have been synthesized by Crumbliss, Shanzer, and
others.65,66,75–79 Another major roadblock was the difficulty of synthesis of high purity
hydroxamate-containing building blocks. Maurer et al utilized O-benzylhydroxylamines and
subsequent alkylation of the open amine in the hydroxamic acid to prevent unwanted side
products from forming. Using this method, they reported the synthesis of mycobactin in 1983.47,80

Many analogs of ferrichrome have been synthesized that incorporate hydroxamate sidechains
on non-peptide scaffolds due to the difficulty of cyclizing peptides81, leaving many fundamental
questions about the coordination environment in ferrichrome unanswered. For example, why are
all three chelating sidechains sequential in the peptide hexamer (AAABBB) instead of alternating
with the non-coordinating residues (ABABAB)? The only two cyclic peptide analogues are
retrohydroxamate ferrichrome, where the hydroxamic acid residue was inverted (i.e., Figure 3.1f
instead of the natural 3.1d), and desmethylhydroxamate ferrichrome, where the methyl groups
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were replaced with hydrogen atoms (Figure 3.1e instead of the natural 3.1d).23,69,71
Retrohydroxamate ferrichrome was shown to be an indistinguishable ionophore of ferrichrome in
activity toward iron-transport and bacteria growth. However, the substitution of the methyl group
for a hydrogen resulted in a complete loss of iron-transport.70,71

The development of synthetic siderophores allowed for new approaches to the treatment of
iron overload diseases.82,83 Traditionally, these synthetic compounds were designed around the
common subunits found in the naturally occurring siderophores. Several examples exist, where
the structures were designed to mimic ferrichrome,69–71,84 desferrioxamine,15,17,53,57 or rhodotoluric
acid.73 Due to the oral inactivity and high doses needed for effectiveness of Desferal, many
studies focused on the design of more efficient iron chelators. For example, several synthetic
analogues of rhodotoluric acid were developed. The naturally occurring rhodotoluric acid is a
dihydroxamic acid compound, which forms 3:2 complexes with iron(III) and is toxic due to water
insolubility. However, the analogues that were developed were more soluble in water and had
three hydroxamic acid groups, allowing for 1:1 complexes to form, thus requiring lower
concentrations for effective iron binding. These compounds were shown to be active as E. coli
growth factors through the ferrichrome mechanism, where the complex was taken into the cell
and the iron(III) released through reduction to iron(II).84,85 Several di- and trihydroxamate
synthetic siderophores have been developed.52,86–89

Several synthetic ferrichrome analogues have been reported. The analogues are related by the
inclusion of three hydroxamic acid groups bridging from a central backbone. Compounds such as
BAMTPH52 and MEDROX83 utilize a rigid tri-substituted benzene backbone, while others, such
as TRENDROX83, TAGP, and TAGE90,91 utilize a more flexible TREN anchor. Control of the
backbone or anchor allows for direct control over the tuning of the binding pocket of the
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hydroxamic acid groups.90 Additionally, peptide analogues, such as peptoids, have the advantage
of inherent biocompatibility and enable straightforward conjugation to proteins and antibodies as
drug imaging agents.31,32,34,36 These properties make peptoids an excellent target for the
development of ligands for the f-elements, specifically the tetravalent actinides. Incorporating
common chelation units found in siderophores, catechols and hydroxamic acids, into cyclic
peptoid backbones allows for straightforward synthesis of siderophore analogues. Initial synthesis
of hexameric cyclopeptoids with monomers allowing for incorporation of these chelation groups
was performed. Ultimately, octameric cyclopeptoids, which would allowed for coordination of
the larger coordination numbers of the tetravalent actinides would be synthesized.

3.2 Results and Discussion

Solid-phase peptide synthesis (SPPS) allows for straightforward synthesis of siderophore
analogues through the customization of both sidechain properties (chelation units, length,
flexibility, solubility) and the cyclic backbone size (hexamer, octamer). Through this route, it is
possible to investigate the structural importance of side-by-side versus alternating chelating
sidechains (e.g. AAABBB vs ABABAB). Manipulation of the sidechain and backbone length
enables investigating previous claims that the atomic spacing between chelating units
(specifically hydroxamic acids) plays an important role in complex stability.86 The lack of chelate
effect in polyhydroxamic acids with large spacer groups would also be easily investigated. 50,52
Finally, the solubility of peptoids is easily controlled through the incorporation of hydrophobic or
hydrophilic side chains in the non-chelating residues. This property easily broadens the possible
applications of these ligands from use in aqueous systems (biological/environmental) to organic
systems (fuel reprocessing).
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The initial consideration for the development of siderophore-inspired cyclopeptoids was how
to incorporate the siderophore metal chelating units into the peptoid backbone. This was done
through the synthesis of monomers which either contained the desired moieties, in this case,
catechols and hydroxamic acids, or allowed for later addition or conversion to the desired
moieties through off-resin chemistry after synthesis of the peptoid backbone. Protecting groups
were necessary to prevent any undesired reactions of the chelating groups during synthesis of the
peptoid backbone. Finally, deprotection of the protected groups needed to be achievable without
destroying the rest of the ligand.

Scheme 3.1: Solid-phase synthesis followed by cleavage and cyclization of peptoids.
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Peptoid backbone (SPPS and cyclization)

The submonomer method: a repeating two-step modular solid-phase peptoid synthesis (SPPS)
was used for the synthesis of linear peptoids, as shown in Scheme 3.1. The two steps, acylation
and halogen displacement (an SN2 reaction), were repeated until the desired length peptoid was
synthesized. The first step, acylation of the resin or peptoid chain by a haloacetic acid, used
bromoacetic acid (BrAA). For all of the reported peptoids BrAA at a concentration of 0.4-1.2M
was used. The BrAA was activated with N,N’-diisopropylcarbodiimide (DIC) and then reacted
with the resin or N-terminus of the peptoid. This reaction was carried out for 1-5 minutes,
depending on the amine residue being acylated. The second step then consisted of the
displacement of the bromine with a primary amine monomer. Amine solutions at 0.25-0.75M in
DMF or DMSO were used and reacted for 1-30 minutes. Each step was repeated twice to ensure
complete reaction and was followed by washes with dichloromethane (DCM) and
dimethylformamide (DMF). The peptoids were synthesized on chlorotrityl chloride resin (CTC,
Figure 3.3), which resulted in a carboxylic acid at the C-terminus after cleavage, a necessity for
cyclization of the peptoid chain. The peptoids were cleaved from the resin with
hexafluoroisopropanol (HFIP) or trifluoroacetic acid (TFA), depending on the presence of acidsensitive side groups. Once cleaved, the linear peptoids were cyclized with carbonyldiimidazole
(CDI) in acetonitrile though an intramolecular condensation between the C- and N-termini.
Subsequent off-resin chemistry was performed when necessary (see catechol and hydroxamic
acid addition). The peptoids were characterized by MALDI-TOF mass spectrometry, which
allowed for the identification of the desired product.
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Figure 3.3: Structure of resin-bound chlorotrityl chloride.

The modular nature of SPPS allows for straightforward customization of the peptoid through
the inclusion of desired properties by the monomers. For example, water-solubility may be
controlled through the use of hydrophilic sidearms, such as pegylated primary amines (e.g.
methoxypropylamine), or hydrophobic sidearms such as phenylethylamine. However, this method
does suffer from several downfalls. The on-resin chemistry is limited to reactions and functional
groups that will not interact with the two SPPS steps. For this reason, off-resin chemistry (preresin monomer synthesis, post-resin cyclization, post-resin monomer conversion/sidearm
addition) is required. More detrimental is the characteristic low yield of resin cleavage. Peptoids
are cleaved from resin through an acid-catalyzed cleavage. In the case of Rink Amide Resin, this
cleavage is performed with trifluoroacetic acid (TFA) and produces an amide at the Cterminus.22,92 CTC can be cleaved with TFA or hexafluoroisopropanol (HFIP). Cleavage with the
very mild HFIP leads to retention of the side chain protecting groups, which is necessary if, for
example, some of the side chains contain amines which must remain protected so that cyclization
only happens with the N-terminus amine. Unfortunately, HFIP cleavage does not lead to good
recovery of peptoid from the resin (<10%). Attempts to optimize cleavage conditions through
changing the acid concentration (5-95%) and time of cleavage (5 min – 24 h) were inconclusive.
A similar study utilizing TFA led to the same inconclusive results. Additionally, the CTC resin is
capable of exchanging the reactive chloride residues for a less reactive hydroxide through
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interaction with water in the air, drastically decreasing the loading capacity of the resin. The CTC
resin can be regenerated through reaction with a reactive chloride, such as thionyl chloride and
will potentially increase loading capacity and yield.

Catecholates

Incorporation of catechols into a peptoid backbone was accomplished by first synthesizing
peptoids with mono-N-Boc-protected diamine sidechains. The diamine monomers were varied to
investigate the effect of changing flexibility and the binding pocket of the chelating units. The
Boc-protection group prevented reaction between the free amine and the bromoacetic acid used
during peptoid synthesis. Cleavage of the peptoid from the resin was performed with hexafluoro2-propanol (HFIP, pKa=9.3), rather than trifluoroacetic acid (TFA, pKa=0.25), to prevent the
premature cleavage of the Boc-groups. After cyclization of the backbone with CDI, the Bocgroup was removed with TFA.

Scheme 3.2: Structure of a hexameric peptoid containing five phenylethylamine (Phe) residues and one diamine
residue (n = 2, 3, 4). A) The diamine is mono-N-Boc protected when added to the peptoid on resin. B) The
peptoid is cleaved from the resin with HFIP, leaving the Boc-group intact. The peptoid is then cyclized with
CDI. C) The Boc-group is removed by TFA.

The catechol unit was incorporated by reaction of 2,3-dihydroxybenzoic acid with the
liberated amine groups on the previously-cyclized peptoid. First, the carboxylic acid on 2,3-
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dihydroxybenzoic

acid

was

activated

using

N-hydroxysuccinamide

(NHS)

and

dicyclohexylcarbodiimide (DCC), as shown in Scheme 3.3.93 This activation allowed for the
coupling of the catechol to the deprotected amine residues in the cyclic peptoid backbone, while
avoiding the laborious protection and deprotection of the phenolic oxygens typically practiced in
the field. The NHS-protecting group suffered low stability and consequently required immediate
use once synthesized.

Scheme 3.3: Off-resin chemistry for catechol incorporation into peptoids. Step 1: NHS-activation of catechol for
subsequent addition to amine residue (n = 2, 3, 4) on cyclic peptoid backbone, Step 2.

Two Boc-protected diamines were added to a cyclic peptoid backbone, tert-butyl-N-(2aminobutyl)carbamate (4CDiamine) and tert-butyl-N-(2-aminoethyl)carbamate (2CDiamine). The
synthesized ligands can be seen in Table 3.1 and Figure 3.4. All peptoids in this series were
synthesized with phenylethylamine residues to increase organic solubility, allowing
straightforward purification after cyclization with CDI by liquid-liquid extraction. NHSdihydroxybenzoic acid was successfully added to one peptoid, (4CDiamine)-Phe5 (Figure 3.5).
This peptoid was characterized by MALDI-TOF (Figure 3.4). The small quantity did not allow
for further testing of the product.
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Table 3.1. Peptoid hexamers and octamers containing catecholate precursors synthesized, cyclized, and
converted to final ligand forms to date. Phe = phenylethylamine, 4CDiamine = tert-butyl-N-(4aminobutyl)carbamate, and 2CDiamine = tert-butyl-N-(2-aminoethyl)carbamate.

Peptoid

Linear

Cyclic

Catechol

(4CDiamine)-Phe5

Yes

Yes

Yes

(4CDiamine)3-Phe3

Yes

Yes

No

(4CDiamine-Phe)3

Yes

Yes

No

(4CDiamine)6

Yes

Yes

No

(4CDiamine)8

Yes

Yes

No

(4CDiamine)4-Phe4

Yes

Yes

No

(4CDiamine-Phe)4

Yes

Yes

No

(2CDiamine)6

Yes

Yes

No

(2CDiamine)-Phe5

Yes

Yes

No

(2CDiamine)3-Phe3

Yes

Yes

No

(2CDiamine-Phe)3

Yes

Yes

No
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Table 3.2. MALDI-TOF results for peptoids containing catecholate precursor residues. All data collected with
HCCA matrix and is reported as m/z. All data presented as m/z in positive mode. Values indicate the product +
H+ and + Na+.

Linear

Cyclic

Deprotected

Calc

Obsd

Calc

Obsd

Calc

Obsd

(4CDiamine)-Phe5

1051.6

1052, 1074

1033.6

1033, 1056

933.5

934, 956

(4CDiamine)3-Phe3

1185.7

1186, 1208

1167.7

1169, 1191

867.5

868, 890

(4CDiamine-Phe)3

1185.7

1186, 1208

1167.7

1169, 1191

867.5

868, 890

(4CDiamine)6

1386.9

1388, 1410

1368.9

1370, 1392

768.6

770, 792

(4CDiamine)8

1814.3

1815, 1837

1796.3

1797, 1819

995.5

996, 1018

(4CDiamine)4-Phe4

1643.1

1644, 1666

1625.1

1626, 1648

1324.8

1326, 1348

(4CDiamine-Phe)4

1643.1

1644, 1666

1625.1

1626, 1648

1324.8

1326, 1348

(2CDiamine)6

1219.4

1220, 1242

1201.4

1202, 1224

600.8

602, 624

(2CDiamine)-Phe5

1023.5

1024, 1046

1005.5

1006, 1028

905.5

907, 928

(2CDiamine)3-Phe3

1101.6

1102, 1124

801.5

802, 824

783.4

784, 807

(2CDiamine-Phe)3

1101.6

1102, 1124

801.5

802, 824

783.4

784, 807

Peptoid
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1119 (+H+)

Linear MW: 1118 (with Boc)

1123 (+Na+)

Cyclic MW: 1100 (with Boc)

With catechol MW: 1172 (no Boc)

1195 (+Na+)

Figure 3.4: MALDI-TOF spectra of (top): linear (4CDiamine)-(Phe)5, (middle) cyclized (4CDiamine)-(Phe)5, and
(bottom) cat-(4CDiamine)-(Phe)5.
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Scheme 3.4: Conversion from Boc-protected sidearm (left) to primary amine (middle) to catechol.
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Figure 3.5: Successfully synthesized cyclopeptoids containing catechol-precursors, or catechol residues.
Octamers are not shown.
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Scheme 3.5: Off-resin chemistry for hydroxamate-containing peptoids. Step 1: synthesis of hydroxamate
precursor monomers through conversion of carboxylic acids to esters with thionyl chloride. Step 2: conversion
of ester to hydroxamate on a cyclic peptoid backbone.

Hydroxamates

Two methods were investigated for the incorporation of hydroxamic acids into cyclic peptoid
backbones. The first attempt involved utilizing monomers containing esters, which were then
reacted with hydroxylamine after the peptoid had been cyclized, to give the hydroxamic acid.
Such ester-to-hydroxamic acid conversions are common in the hydroxamate literature, albeit most
commonly with monohydroxamates where low conversion yields are not problematic.
Substituted benzoic acid precursors were converted from carboxylic acids to esters using thionyl
chloride, as shown in Scheme 3.5.94 4-(aminomethyl)benzoic acid was converted into the methyl
ester (BH) and ethyl ester (EtBH) through reactions with the corresponding alcohol. A third
hydroxamate precursor, diethyl aminomalonate hydrochloride salt (AMA) was bought
commercially and used without further purification. The BH and EtBH amines were obtained as
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HCl salts after synthesis. The presence of the chloride counterion resulted in the conversion of the
reactive bromoacetyl to a more inert chloroacetyl. This inactivation was countered using catalytic
potassium iodide and longer reaction times during the SPPS acylation step (30 min).

Figure 3.6: Successfully synthesized hexa- and octa-cyclopeptoids containing ester monomers.
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The monomer synthesis was hindered by nearly-intractable solubility issues with aminomethyl
benzoic acid, due to its ability to exist in a zwitterionic state that is difficult to solubilize. The
ester product (BH, EtBH) also had low solubility in DMF, the solvent used for SPPS. A mixture
of DMF/dimethylsulfoxide (DMSO) was used to dissolve the monomer, catalytic iodide and
sodium carbonate, for deprotection of the ammonium salt formed during ester formation. The
solubility issues limited peptoid loading efficiency, along with the issues mentioned above.

Once the peptoid was cyclized, the esters were converted to hydroxamic acids through a
reaction with hydroxylamine and catalytic potassium cyanide (KCN), as shown in Scheme 3.5.
The catalytic KCN supposedly led to an acyl-cyanide intermediate, followed by nucleophilic
substitution by an amine.94 This method was followed, after several trials with the traditional
hydroxamic acid synthesis from esters, which involved the reaction with hydroxylamine
hydrochloride, due to the low efficiency of this conversion.95,96 The need to convert multiple
residues on one molecule required the highest possible efficiency, due to difficult purification and
low yields of the final product. Unfortunately, the use of KCN still led to a mixture of the
hydroxamate and carboxylate products, a recognized, but understated issue in the literature when
it comes to polyhydroxamic acids.

An additional monomer, diethyl aminomalonate (AMA) was investigated (Scheme 3.5). When
this amine was used as the terminal residue during synthesis, an AMA-(Phe)5 peptoid was
successfully synthesized, cleaved and cyclized (Figure 3.6). When AMA was used in any position
other than the terminal amine, the desired product did not form. The formation of a
diketopiperazine (DKP) occurred through reaction between subsequent amine residues and the
ester arm of the AMA residue (Scheme 3.6). The formation of a DKP prevents any subsequent
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addition of amines or cyclization of the peptoid, severely limiting the use of AMA for peptoid
design.

Scheme 3.6. Diketopiperazine formation by AMA during SPPS.

Table 3.3: Peptoid hexamers and octamers containing ester monomers for conversion to hydroxamic acid
moieties. BH = methyl 4-(aminomethyl)benzoate, EtBH = ethyl 4-(aminomethyl)beozoate, AMA = diethyl
aminomalonate, Phe = phenylethylamine, MPA = methoxypropylamine.

Peptoid

Linear

Cyclic

Hydroxamate

BH-Phe5

Yes

Yes

Yes*

(BH)3-(Phe)3

Yes

Yes

No

(BH-Phe)3

Yes

Yes

No

EtBH-Phe5

Yes

Yes

No

(EtBH)3-(Phe)3

Yes

Yes

Yes*

(EtBH-Phe)3

Yes

Yes

No

(EtBH)4-(Phe)4

Yes

Yes

Yes*

(EtBH-Phe)4

Yes

Yes

No

(AMA)-(Phe)5

Yes

Yes

No

*The final product was an impure mixture of compounds (-C(O)OH, -C(O)NHOH, etc)

Table 3.3 and Figure 3.6 show the ester-containing peptoid oligomers that were synthesized
and cyclized. Along with hexamers, several octamer peptoids have been synthesized to
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incorporate four bidentate ligand arms for actinide coordination as well as hexamers designed for
aqueous solubility through the presence of methoxypropylamine (MPA) sidechains rather than
phenylethylamine.

Table 3.4. MALDI-TOF results for peptoid hexamers and octamers containing ester monomers for conversion to
hydroxamic acid moieties. All data presented as m/z in positive mode. Values indicate the product + H+ and +
Na+.

Linear

Cyclic

Hydroxamate

Peptoid

Calc

Obsd

Calc

Obsd

Calc

Obsd

BH-Phe5

1029.5

1029, 1051

1010.5

1033, 1049

1011.5

1012, 1034*

(BH)3-(Phe)3

1116.5

1117, 1139

1098.5

1100, 1122

1102.4

No

(BH-Phe)3

1116.5

1117, 1139

1098.5

1100, 1122

1102.4

No

EtBH-Phe5

1042.5

1043, 1065

1024.5

1026, 1048

1011.5

No

(EtBH)3-(Phe)3

1117.3

1118, 1140

1099.3

1100, 1122

1102.2

1103, 1125*

(EtBH-Phe)3

1117.3

1118, 1140

1099.3

1100, 1122

1102.2

No

(EtBH)4-(Phe)4

1538.7

1540, 1562

1520.7

1522, 1544

1468.6

1470, 1492*

(EtBH-Phe)4

1538.7

1540, 1562

1520.7

1522, 1544

1468.6

No

(AMA)-(Phe)5

1038.5

1061, 1077

1020.5

1043, 1077

994.5

No

*The final product was an impure mixture of compounds (-C(O)OH, -C(O)NHOH, etc).
Only C(O)NHOH listed.

A second route was investigated, in an attempt to avoid conversion issues of polyhydroxamic
acids, along with solubility issues. This method involved the synthesis of amino acid-based
monomers with O-tert-butylbenzyl hydroxamic acid. The use of the O-protected hydroxamic acid
prevented decomposition of the hydroxamic acid into carboxylic acid, and interaction of the unit
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in sub sequent chemistry and allowed for more straightforward characterization and purification
of the product.89,97,98 O-tert-butylbenzyl hydroxylamine was synthesized through a reaction of
tert-butylbenzyl bromide and N-hydroxyphthalimide (Scheme 3.7, 1), followed by deprotection of
the phthalimide group with excess hydrazine (Scheme 3.7, 2; see further discussion of this route
in the subsequent chapter).99–102

Scheme 3.7. Synthesis of O-tert-butylbenzyl hydroxylamine.

Amino acids were used due to the presence of a primary amine, for incorporation into a
peptoid, and a carboxylic acid for conversion to the hydroxamic acid. The target amino acids
were glycine (Gly), β-alanine (β-Ala), and γ-aminobutyric acid (GABA) (Figure 3.7). In order to
convert the carboxylic acid into an O-protected hydroxamic acid, protection of the nitrogen was
required. The use of three amino-protecting groups was attempted, including phthalimide, Boc,
and Fmoc.

Figure 3.7. Structures of 1) glycine, 2) β-alanine, and 3) γ-aminobutyric acid.

Due to the success with using the phthalimide protecting group during the synthesis of
protected hydroxylamines, this group was initially investigated. The target amino acid and
phthalic anhydride were melted and refluxed gently for four hours. Upon cooling, a white solid
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was formed, which was purified through recrystallization with water (Scheme 3.8, Step 1).103 This
reaction was successfully carried out with β-Ala and GABA. The N-phthalic amino acids were
then converted to their corresponding acid chlorides through reflux with thionyl chloride in
dichloromethane, followed by nucleophilic acyl substitution with the O-tert-butylbenzyl
hydroxylamine (Scheme 3.8, Step 2). The final step required deprotection of the phthalimide
group to give a primary amine group, which would allow for use in SPPS. Unfortunately, the
hydroxamic acid unit was susceptible to acid- and base-catalyzed deprotection and/or
decomposition into carboxylic acids. The hydrazine deprotection conditions used for the O-tertbutyl hydroxylamine synthesis were too harsh for the hydroxamic acid group. NMR and TLC
showed evidence of removal of the hydroxamic acid group along with deprotection of the
phthalimide group. Conditions were altered to use stoichiometric hydrazine, rather than excess,
but this method still led to a mixture of products (Scheme 3.8, Step 3).

Scheme 3.8: Hydroxamate-amino acid derivative synthesis through phthalimide protection of the amine group.
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The Boc protecting group can be removed in mildly acidic conditions, which would possibly
allow for deprotection without removing the hydroxamic acid. Di-tert-butyl dicarbonate was
reacted with the amino acid and a mild base to protect the amine terminus (Scheme 3.9, Step 1).
Once the Boc group was present, the carboxylic acid was converted to an acid chloride, the Oprotected hydroxylamine added to form a hydroxamic acid, and the Boc group removed by TFA
(Scheme 3.9, Step 2). Unfortunately, the acylation of the carboxylic acid by thionyl chloride
resulted in the premature removal of the Boc group. In an attempt to circumvent the issue, efforts
to activate the carboxylic acid through reaction with a carbodiimide, dicyclohexylcarbodiimide
(DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (Scheme 3.9, Step 3). The
activation by carbodiimide produces a urea sideproduct. DCC produces a solid urea, which is
removed by filtration. However, trace amounts of DCC can remain in the product and are difficult
to fully remove. EDC produces a water-soluble urea, which could be removed by extraction.
Neither activating group led to clean addition of the O-tert-butyl hydroxylamine. Removal of the
urea sideproduct by filtration or extraction was not successful.

The use of the Fmoc and Boc protecting groups is common in peptide and peptoid synthesis.
Once the Boc group was ruled out as a possibility, the Fmoc group was investigated. Initial
attempts to synthesize Fmoc-GABA required purification through column chromatography and
proved difficult,104 but fortunately unnecessary because both Fmoc-GABA-OH and Fmoc-β-Ala
are commercially available, making this route more attractive than the phthalimide and Boc
routes. The Fmoc-amino acids were acylated by thionyl chloride, followed by substituted by the
O-tert-butyl hydroxylamine.105 The final step required the deprotection of the Fmoc group by 4methylpiperidine followed by purification by column chromatography. While the final step was
successful, optimization is necessary for large scale synthesis and subsequent use in SPPS.
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Scheme 3.9: Boc-protected amino acid synthesis of hydroxamic acid monomers. Step 1: N-Boc protection of
amino acid, Step 2: Acylation of the carboxylic acid led to deprotection of the Boc group instead of acylation,
Step 3: Activation of the carboxylic acid by carbodiimide (DCC is shown) and O-tert-butyl hydroxylamine.

Scheme 3.10: Fmoc-amino acid synthesis of hydroxamic acid monomers. Step 1: Conversion of Fmoc-AA-OH to
Fmoc-AA-Cl and reaction with O-protected hydroxylamine . Step 2: Deprotection of Fmoc group with 4methylpiperidine.

The most promising route toward amino acids containing an O-protected hydroxamic acid
group is shown in Scheme 3.10. The Fmoc protected amino acids are commercially available,
obviating a step which was necessary for the phthalimide and Boc routes. The Fmoc group is
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stable to the acidic conditions necessary for conversion of the carboxylic acid into an acyl
chloride, which is necessary for addition of the hydroxylamine and formation of the hydroxamic
acid. The Fmoc group also allows for straightforward purification through chromatography.
However, the final step, deprotection of the Fmoc group, requires optimization. Large scale
synthesis of the amino acid monomers would allow for use in SPPS.

3.3 Conclusions

Peptoids offer a unique opportunity for straightforward customization of large macrocyclic
molecules with biological relevance. Inspiration taken from natural siderophores, such as
ferrichrome and enterobactin, was the driving force for the design of cyclopeptoids containing
catechol and hydroxamic acid chelating groups. By incorporating these units into a cyclic peptoid
backbone, not only could a new class of ligands be developed, but several structural properties
could be investigated. Peptoid synthesis utilizes primary amines, allowing for manipulation of
properties, such as the order of chelating residues (AAABBB versus ABABAB), size of the
backbone (hexamer versus octamer), length of the sidechains, and solubility. Through
manipulation of these properties, strict control over the topology of the binding pocket is possible,
allowing for the targeting of specific metals, specifically the tetravalent actinides.

A catechol monomer cannot be directly used in SPPS without extremely laborious orthogonal
protecting groups due to interaction with the reagents during the backbone synthesis. However,
by using a mono-N-Boc protected diamine, it was possible to synthesize and cyclize a peptoid
chain with available sites for subsequent catechol conjugation. NHS-activated 2,3dihydroxybenzoic acid was successfully added to the peptoid through reaction with the previously
Boc protected amine—a hexamer containing one catechol group was successfully synthesized, as
shown by MALDI-TOF. Optimization of the NHS-activation is necessary to push this route
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forward. However, the initial step of synthesizing cyclopeptoids with open amines has been
successful, as shown in Table 3.1 and Figure 3.5.

The incorporation of multiple hydroxamic acids into a peptoid required investigation of
multiple synthetic approaches. The synthesis of hydroxamic acids from various functional groups,
such as carboxylic acids and esters is well-known, with low-to-moderate yields, particularly for
monohydroxamic acids. However, the conversion of multiple esters into hydroxamic acids,
Scheme 3.5, did not prove successful. The ester monomer derivative of aminomethyl benzoic acid
was plagued by solubility issues, which lowered the synthetic efficiency. Additionally, the
conversion from ester to hydroxamic acid did not proceed cleanly and led to a mixture of
products, including the ester staring material, hydroxamic acid product and carboxylic acid.
Purification of resulting peptoids of molecular weights ~1000-2000 with a mixture of carboxylic
and hydroxamic acids is quite complicated. Coupled with the low yield of peptoid cleavage from
resin, this problem was not easily resolved.

In response, a new method was devised, which aimed to incorporate the hydroxamic acid
group into the synthesis of the cyclopeptoid by use of an O-protected hydroxylamine. The
conversion of an amino acid to the corresponding hydroxamic acid derivative required protection
of the amine residue. Several protecting groups were attempted, phthalimide, Boc and Fmoc.
Each protecting group was successfully used to protect the amino acids β-alanine and γaminobutyric acid. The phthalimide-amino acids and Fmoc-amino acids were subsequently
converted to their corresponding acid chlorides, followed by addition of the O-protected
hydroxylamine. The Boc group was removed upon attempts to convert the amino acids to the acid
chloride. Deprotection of the phthalimide group removed the hydroxamic acid instead. The most
promising route was through the use of the Fmoc amino acids, as shown in Scheme 3.10.
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Optimization of the final deprotection of the Fmoc amine will allow for direct use in SPPS. Once
the peptoid has been synthesized and cyclized, removal of the benzyl groups through
hydrogenation will lead to hydroxamic acids.

3.4 Future Directions

Two promising routes toward siderophore-inspired cyclopeptoids were developed. Once the
routes are optimized, forward progress will involve study of the stability constants of complex
formation with various metals, primarily Fe(III) for the hexameric peptoids, and Ln(III) and/or
An(IV) for the octameric peptoids.

Complex formation with transition metals and tetravalent actinides

Initially, complexes should be synthesized with the peptoids and first row transition metals,
Fe(III), Cu(II) and Co(II). These non-radioactive complexes will be easier to characterize and can
be compared to a wide body of literature on metal-hydroxamate and –catecholate complexes.
Fe(III) is especially well known for forming various colored complexes with both hydroxamates
and catecholates, which will allow for rapid visual validation of coordination by the peptoids
which is particularly important given the small scales of peptoid chemistry. 106,107 Complexes will
be formed through equimolar reactions of the metal and peptoid. The use of hydroxamate- and
catecholate-containing sidearms will likely lead to interaction between the peptoid and metal
ions, similar to those seen with siderophores such as ferrichrome and enterobactin (Figure 3.1).
Actinide complexes using Th(IV) and U(IV) will be synthesized in aqueous conditions using
water-soluble peptoids with methoxypropylamine sidechains using standard literature
methods.108,109
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Selectivity for various metal ions can be achieved by tuning the length of the cyclic backbone
and controlling the placement and number of metal-binding residues. For the higher coordination
numbers of the actinides, octamers will be used, which will allow for the incorporation of more
hydroxamate or catecholate residues. The solubility will also be controlled through the use of
phenylethylamine or methoxypropylamine residues.

Characterization of peptoid complexes

The peptoid-metal complexes can be characterized by UV-vis, FTIR, and NMR. Ultimately,
diffraction quality crystals will be studied, if they can be grown. Once the interaction of the
peptoids with the early transition metals is understood, complexation with tetravalent actinides,
Th(IV) and U(IV), will be performed. The solution thermodynamics will be studied through
potentiometric titrations, which will also allow for study of the complexation in complex
environments, similar to those that actinides are often found in, such as ocean water or nuclear
waste. Computational geometry optimization will further enhance understanding of how to best
control selectivity in ligand design.

3.5 Experimental

Chemicals: 2-Chlorotrityl chloride resin was obtained from Aapptec. Bromoacetic acid, DIEA,
4-(aminomethyl)benzoic acid, N-hydroxyphthalimide, triethylamine, N,N’-carbonyldiimidazole
(CDI), and γ-GABA were obtained from Chem-Impex. DMF was from BDH Chemicals. DCM
was from Fisher Scientific. DIC, HFIP, TFA, p-tert-butylbenzyl bromide and β-alanine were
obtained from Oakwood Chemicals. 2-Phenylethylamine was from Alfa Aesar. Hydrazine
monohydrate was from Beantown Chemicals. Fmoc-β-Ala and fmoc-γ-GABA were from AK
Scientific.
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Solid-phase peptoid synthesis. All peptoids were synthesized manually with SPPS methods on
chlorotrityl chloride (CTC) resin with 0.51 mmol/g. CTC resin (1 gram) was swollen in DCM (10
mL, 5 min) with stirring. The resin was activated through the addition of bromoacetic acid
(BrAA, 0.13 M, 10 mL) and diisopropylethylamine (DIEA, 0.9 mL) for 60 minutes. This was
performed two times. The resin was washed with DCM x3, DMF x3, DCM x3, MeOH x3 to
remove unreacted BrAA and to cap unreacted sites on the resin. The resin was swelled again
(DCM, 10 mL, 5 min) before addition of an amine. Amine solution concentrations were varied
depending on the amine (0.25 – 1.5 M) and the amines were stirred with the activated resin for
various times (1 – 30 min). This step was performed twice to ensure optimal reaction. Following
the amine step, the resin was washed with DMF (3x). The amine was then acylated through
reaction with BrAA (0.5 M, 10 mL, 1 – 30 min) and DIC (0.640 mL). The acylation step was
dependent on the amine. The peptoid was built to a desired length by repeating the addition of
amine, followed by acylation by BrAA and DIC activation. Each step was repeated twice to
increase yield and purity. Each step was followed by washing with DMF (3x). The synthetic
scheme is shown in Scheme 3.1. The specific reaction conditions are listed in Table 3.5.

Table 3.5. Synthetic conditions of various amines for SPPS.
BrAA (M) BrAA (min) Amine (M)
Amine
0.4
1
0.5
Phe
0.4
1
0.75
AMA
0.4
1
0.75
BH
0.4
1
0.75
EtBH
0.4
1
0.25
4CDiamine
0.4
1
0.25
2CDiamine

Amine (min)
1
30
30
30
30
30

Peptoid cleavage. A test cleavage of each peptoid was performed for preliminary identification
by MALDI. A small amount of resin was stirred in a mixture of 80% HFIP/DCM for 10 min. The
solvent was dried down by nitrogen and the resin was resuspended in 90% ACN/water and
filtered for testing. Full cleavage was carried out by stirring the resin in 10 mL of 80%
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HFIP/DCM or 5% TFA/DCM for 1 hour. This was performed twice. The solution was removed
from the resin and dried down. The cleavage conditions were changed depending on the presence
of acid-sensitive protecting groups (Boc).

Peptoid cyclization. The cleaved peptoid was dissolved in DCM and stirred for 18 hours with
excess CDI (3 eq). The product was purified by washing with water (3x) and dried over sodium
sulfate. The solvent was removed in vacuo.

Monomer synthesis.

Methyl- and ethyl-4(aminomethyl)benzoate (BH and EtBH): 4-(aminomethyl)benzoic acid
(AMBA) (1 eq) was dissolved in the corresponding alcohol (methanol or ethanol) and excess
thionyl chloride. The reaction was refluxed overnight. The solvent was removed in vacuo to give
a white solid product.
BH: 1H NMR (500 MHz, D2O): 8.04-8.02 δ (d, J = 8.30 Hz, 2H), 7.54-7.52 δ (d, J = 8.30 Hz,
2H), 4.23 δ (s, 2H), 3.90 δ (s, 3H). 13C NMR (500 MHz, D2O): 138.0 δ, 130.2 δ, 129.0 δ, 52.8 δ,
42.7 δ. 85% yield.
EtBH: 1H NMR (500 MHz, D2O): 8.07-8.05 δ (d, J = 8.30 Hz, 2H), 7.55-7.54 δ (d, J = 8.30 Hz,
2H), 4.40-4.36 δ (m, J = 7.13 Hz, 2H), 4.25 δ (s, 2H), 1.38-1.35 δ (t, J = 7.17 Hz, 3H). 41% yield.

Hydroxamate synthesis

BH/EtBH Residues: The cyclized peptoid containing BH or EtBH residues was reacted with
excess hydroxylamine hydrochloride and catalytic potassium cyanide in dichloromethane
overnight at room temperature.
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O-tert-butyl hydrodroxylamine: Step 1: Minimal N,N-dimethylformamide (300 mL) was used
to dissolve N-hydroxylphthalimide (1 eq, 24.4 g) in a round-bottom flask, resulting in a yellow
solution. Slowly, triethylamine (1 eq, 20.9 mL) was added to the reaction, which turned the
reaction mixture dark red. 4-t-butylbenzyl bromide (1 eq, 27.5 mL) was then added. After less
than a minute, the reaction began to lighten, as solid began to form. The reaction was stirred at
room temperature under ambient conditions. After 48 hours, enough solid was present to give the
reaction an orange hue. The volume was doubled with deionized water, precipitating the product
as a white solid, which was collected by vacuum and dried (43.4 g, 94%). 1H NMR (500 MHz,
DMSO): 7.19-7.17 δ (d, J = 10.25 Hz, 2 H), 6.86-6.84 δ (d, J = 10.25, 2 H), 3.73 δ (s, 2 H), 1.50
δ (s, 9 H). 13C NMR (500 MHz, DMSO): 156.6 δ, 156.3 δ, 129.5 δ, 129.4 δ, 129.0 δ, 128.9 δ,
126.4 δ, 126.3 δ, 115.5 δ, 67.0 δ, 45.9 δ, 44.6 δ, 28.4 δ, 27.7 δ.

Step 2: Hydrazine monohydrate (10 eq, 130 mL) was slowly added to a solution of 1 (1 eq, 41.4
g) in chloroform (400 mL). The reaction mixture was stirred under reflux. Hydrazine was added
every eight hours, three times for a total of 30 eq. After 24 hours, the reaction was cooled and the
product extracted into dichloromethane three times, then dried over anhydrous sodium sulfate.
The solvent was removed under reduced pressure, resulting in a viscous, colorless liquid (23.5 g,
98%). 1H NMR (500 MHz, DMSO): 7.37-7.33 δ (t, J = 8.31 Hz, 2H), 7.26-7.22 δ (t, J = 8.31),
4.53 δ (s, 2H), 1.28 δ (s, 9H). 13C NMR (500 MHz, DMSO): 150.28 δ, 135.71 δ, 128.31 δ, 125.35
δ, 77.18 δ, 34.69 δ, 31.63 δ.

Phthalimide-protected amino acids: The target amino acid (1 eq) and phthalic anhydride (1 eq)
were refluxed for 4 hours. Once cooled, a colorless solid formed. This solid was recrystallized in
hot water, to produce a white solid. Yield: β-alanine (87%) and γ-GABA (85%).
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β-Alanine: 1H NMR (500 MHz, CDCl3): 7.86-7.84 δ (m, J = 3.11 Hz, 2H), 7.73-7.71 δ (m, J =
3.11 Hz, 2H), 4.01-3.98 δ (t, J = 6.12 Hz, 2H), 2.81-2.78 δ (t, J = 6.12 Hz, 2H).
γ-GABA: 1H NMR (500 MHz, CDCl3): 7.86-7.84 δ (m, J = 3.03 Hz, 2H), 7.73-7.71 δ (m, J =
3.03 Hz, 2H), 3.77-3.75 δ (t, J = 7.44 Hz, 2H), 2.43-2.40 δ (t, J = 7.44 Hz, 2H), 2.03-2.00 δ (m, J
= 7.44 Hz, 2H).
General acylation of amino acids: Protected amino acids (β-Ala, γ-GABA) (1 eq) were refluxed
in excess thionyl chloride (5-10 eq) in minimal DCM overnight. The solvent was removed in
vacuo. The products were not isolated before moving to the next step. Quantitative yields were
assumed for the subsequent reactions.

Fmoc-AA-Cl + O-t-bu-hydroxylamine: The acylated fmoc-amino acid (1 eq), sodium carbonate
(2 eq) and O-t-bu-hydroxylamine were stirred at room temperature overnight in DCM. A white
solid immediately formed with the addition of the hydroxylamine. The solid was removed by
filtration and the solvent was removed in vacuo. The final product was not cleanly isolated.

Catechol synthesis

2,3-dihydroxybenzoic acid (1 eq) was reacted with DCC (1 eq) and N-hydroxysuccinimide (1 eq)
in 1,4-dioxane at room temperature. The reaction was stirred overnight. The solvent was removed
in vacuo and the product was purified by column chromatography (MeOH/DCM) to give a pure,
final product, 21% yield. 1H NMR (500 MHz, DMSO): 10.06 δ (s, 2H), 9.62 δ (s, 2H), 7.30-7.28
δ (d, J = 8.34 Hz, 2H), 7.14-7.11 δ (d, J = 8.34 Hz, 2H), 6.83-6.78 (t, J = 8.34 Hz, 2H), 2.87 δ (s,
8H).
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Boc deprotection: The cyclized peptoids containing boc-protected amine residues were stirred at
room temperature in 95% TFA/DCM overnight. The solvent was removed by nitrogen.

The NHS-activated 2,3-dihydroxybenzoic acid (1 eq/amine) and triethylamine (2 eq/amine) were
stirred at room temperature in DCM with the deprotected cyclized peptoid overnight.
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CHAPTER FOUR

ETHYLENEDIAMINE POLYHYDROXAMIC ACID LIGAND DESIGN FOR FELEMENT COORDINATION

4.1 Hydroxamic acid introduction

The synthetic saga of understanding the complexities of hydroxamic acid chemistry began in
1869 with H. Lossen’s discovery of the reaction between ethyl oxalate and hydroxylamine,
producing oxalohydroxamic acid (Scheme 4.1, A). Later work by W. Lossen demonstrated the
existence of multiple tautomers of hydroxamic acids, through the production of three products
from the reaction of hydroxylamine and benzoyl chloride: benzohydroxamic acid, benzoyl
benzohydroxamate, and dibenzoyl benzohydroxamate. These products could only have been
produced through the presence of multiple intermediates, suggesting the existence of three
possible tautomers of the hydroxamic acid product.1,2 Later, in 1872, W. Lossen discovered what
is now known as the Lossen Rearrangement through the pyrolysis of N-(benzoyloxy)benzamide
to phenyl isocyanate (Scheme 4.1, B).2 The majority of early work on hydroxamic acids focused
on understanding their complex structural chemistry, however, the lack of understanding of the
structural forms of hydroxamic acids in solution led to a significant issue with fully understanding
the possible binding modes present.3 Their biological and medicinal potentials were not heavily
investigated until the latter half of the 1900s, when multiple classes of hydroxamic acidcontaining siderophores, naturally occurring small molecules that aid in the bacterial metabolism
and transportation of iron(III), were isolated and studied for biological uses.4–6
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Scheme 4.1: A) Reaction of ethyl oxalate and hydroxylamine to form oxalohydroxamic acid. B)Lossen
rearrangement of N-(benzoyloxy)benzamide (1) to phenyl isocyanate (2) and benzoic acid.

In early work, the differentiation between N- and O-acylated hydroxylamines (Figure 4.1) was
not possible due to the lack of spectrophotometric analysis tools. However, through the use of
infrared analysis, a difference in carbonyl stretch was noted for each form, 1670-1640 cm-1 and
1760-1730 cm-1 respectively. Solid state analysis of acetohydroxamic acid further pointed to the
existence of the N-acylated product, more commonly known as the hydroxamic acid. The use of
UV, IR, ESR, mass and NMR have all pointed to the hydroxamic acid being the dominant form,
both in solid state and solution. Direct proof of the hydroxamic acid was further obtained using
2D NMR (15N and 1H) to show the N-H correlation. Thermodynamically, the hydroxamic acid is
preferred. The kinetically O-acylated product has been shown to quickly rearrange to the other
form.7

Figure 4.1: Structures of N- and O-acylated hydroxylamine
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Hydroxamic acids are known to exist in two distinct forms, the keto (D) and enol (E) form,
through the transfer of a proton between oxygen atoms (Scheme 4.). The keto form is believed to
predominate in solid and solution state.2,7–9 The ambiguity of the anionic form has been an issue
throughout the study of the hydroxamic acids. Plapinger studied the UV-vis shift of various
hydroxamic acid derivatives in an attempt to clarify the structure of the anionic form in solution.
He noted both a red and blue shift for benzohydroxamic acid anions, but only a single shift for
both O- and N-methylhydroxamic acids (red and blue, respectively). From this observation,
Plapinger hypothesized that at least two anionic forms exist, with the possibility of a third form.
He attributed the blue shift to form A and the red shift to form B and/or C (Scheme 4.2).8 Later IR
studies of benzohydroxamic acid by Steinberg further confirmed the existence of multiple anionic
forms in solution through the isolation of forms A and B (Scheme 4.2). However, an inability to
neither confirm nor deny the existence of form C led him to conclude that the third form could
exist, but in a much lower concentration, where [A] ≈ [B] >>> [C] (Scheme 4.2).2,9

Scheme 4.2: A-C) Possible anionic forms of hydroxamic acids, D) keto and E) enol protonated forms.2,9

Hydroxamic acids are weakly acidic, primarily due to the OH group (pKa 8-9). They are
weaker acids than their corresponding carboxylic acids (pKa 4-5), but more acidic than the
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amides (pKa 20-22).10,11 Early literature primarily insisted the acidity was strictly from the
hydroxyl group (e.g. Scheme 4.2, A),2,7,12,13 with few exceptions suggesting the presence of an Nanionic tautomer (e.g. Scheme 4.2, B, left).8,13 This weakly acidic nature can be attributed to
suppression of the basicity of the amine group via a resonance structure that leads to a partial
double-bond character for the nitrogen (e.g. Scheme 4.2, B, right and E), a phenomenon also
noted in amides.14 Exner and Böhm used gas phase calculations to show the destabilizing
inductive effect from the hydroxyl group allows for higher acidity of the nitrogen atom. A
computational study by Exner in 2003 suggested that resonance was responsible for one half of
the acidity of hydroxamic acids, compared to one-third in amides and one-quarter in carboxylic
acids. The acidity of the nitrogen atom is strengthened by electron-withdrawing substituents.15
The acidity of the compound was further suggested to not only come from the anionic form, but
also from the negative inductive effect of the hydroxyl group, leading to a higher negative charge
on the nitrogen atom.16

Figure 4.2: (Left) alkylation product, (Right) acylation product.

Alkylation of hydroxamic acids selectively leads to the O-alkylated product due to the αeffect, which leads to increased nucleophilicity of the hydroxyl oxygen atom due to the presence
of the lone pair electrons on the nitrogen atom (Figure 4.2, left). Mixed anhydride hydroxamic
acids can be synthesized through acylation, giving the O-esters (Figure 4.2, right).3,7 When
heated, or in the presence of strong base, hydroxamic acids are known to go through the Lossen
Rearrangement when in contact with an alkylating agent, where they rearrange into
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isocyanates.2,7,17,18 However, Hoshino has shown evidence of a self-propagated Lossen
rearrangement in base without the need of the alkylating agent.17,18 Hydroxamic acids can also
undergo acid and base-catalyzed hydrolysis, leading to the corresponding carboxylic acids.19,20

Scheme 4.3: Mechanism of base-mediated Lossen rearrangement

4.2 Hydroxamic acid ligands

Hydroxamic acids are capable of acting as mono- or bidentate ligands through the oxygen
atoms, but can also act as monodentate ligands through the nitrogen atom, if unsubstituted.6,21 The
loss of a proton from the hydroxy group, followed by a ring closing by the carbonyl allows for the
formation of a stable five-membered metallocycle during metal coordination.14 Some metal-HA
complexes are highly colored and have been used in the spectrophotometric and gravimetric
analysis of the involved metals.14,21,22 Due to neutral charge of many hydroxamate-metal
complexes, they can be extracted from aqueous systems by most immiscible organic
solvents.14,23,24

At low pH, a 1:1 ligand-to-metal complex is typically formed, with increasing L:M ratios as
the pH increases. For example, in highly acidic solutions, hydroxamic acids form 1:1 complexes
with iron(III), creating a deeply purple solution in aqueous media. As the pH increases, the 2:1
complex forms, followed by the 3:1 near a neutral pH, slowly turning the solution to a red-orange
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color.11,25 This behavior of increasing L:M stoichiometry with pH is typical for acidic groups
capable of metal coordination, such as carboxylic acids. The pKa values can vary from 7-11,
depending on the presence of groups with negative or positive inductive effects, such as halides
or alkyl groups, respectively. The negative inductive effect decreases the pka value, while the
positive inductive effect increases the pka value.22

4.3 Hydroxamic acids and actinides
Discovery of the potential of the f-elements in the late 19th and early 20th centuries instigated
the beginning of the nuclear age, leading to the formation of many industries, including nuclear
weapons, energy and radiopharmaceuticals.26–28 While some actinides exist naturally, for
example, thorium and uranium, others such as plutonium have largely been introduced into the
environment by human means. As the demand for actinide use increased, so did their unwanted
presence in the environment. An increased demand further pressured the actinide mining industry,
requiring more efficient mining methods.28 The complex chemistry of the actinides complicates
the development of selective removal methods, particularly due to their wide range of oxidation
states and the competitive environments they typically need to be removed from.27

Many approaches have been studied for the selective removal of actinides from various
environments such as nuclear fuel waste, environmental water samples, and the human body.27
The reprocessing of nuclear waste utilizes liquid extraction and various ligands to aide in the
separation of uranium and plutonium from the other fission products present at the end of the fuel
cycle. The PUREX process, developed during the Manhattan Project, is still the primary process
used worldwide. It uses tributyl phosphate to help separate uranium and plutonium into an
organic phase out of a nitric acid solution.28 Environmental remediation and mining techniques
have studied the use of highly coordinating ligands containing carboxylates and hydroxamates,
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but selectivity issues lead to the inability to sufficiently separate only the target metal(s) from
solutions containing other naturally occurring metals such as iron. The same issues exist with the
selective removal of actinides from the body without the removal of biologically necessary metal
ions.27,29,30

Siderophores, biological iron(III) scavengers, have often been used as the basis for actinide
ligand design due to the similar charge/ionic radius ratio between iron(III) and
plutonium(IV).26,27,31,32 Ferrichrome, the first isolated and characterized siderophore, contains
three hydroxamate binding moieties, making it a strong chelator of the ferric ion. Hydroxamates
have a long history as potent actinide ligands, due the ability to accommodate the high
coordination numbers of actinides through multidentate binding.27,32,33

Several factors contribute to the stable complexes formed by hydroxamic acids and actinides.
The hard acidic nature of the early actinide metals gives a tendency to preferentially bind hard,
oxoligands such as the hydroxamic acids.26 A small bite angle allows for higher coordination
numbers.27,34 The small bite angle also allows for the formation of a stable five-membered ring
when coordinated to the actinides. This both increases stability and selectivity of the hydroxamic
acid actinide complexes.

Ligand

examples

(Waste

management,

radiopharmaceuticals,

chelation

therapy,

mining/environmental)

Simple hydroxamic acids, such as aceto- (Figure 4.3, AHA) and formohydroxamic acid
(Figure 4.3, FHA) were investigated early in actinide research for their ability to increase
selective removal of metals during fuel waste reprocessing.35 Both molecules were found to be
effective stripping agents for tetravalent actinides, Pu(IV) and Np(IV). FHA was specifically
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shown to allow the selective retainment of Pu(IV) and Np(IV) in an aqueous nitric acid solution,
while U(VI) was removed by a tributylphosphate/kerosene organic extractant.36 FHA has also
been shown to quickly reduce Np(VI) to Np(V) while not affecting U(VI), allowing for the
subsequent extraction of Np(V) in the aqueous solution.34–39 The formation of hydroxylamine
from the hydrolysis of hydroxamic acid in nitric acid contributes to the slower complexation and
reduction of Pu(IV) to Pu(III).36,37 At high nitric acid concentrations, U(VI) does not coordinate
with formo- or acetohydroxamic acid, allowing for an effective separation of Np(VI) and Pu(IV)
from U(VI).36 Aromatic hydroxamates have also been investigated to improve the stability of the
hydroxamates to hydrolysis at extreme pH (Figure 4.3, 1,2-HOPO).34,40,41

Figure 4.3: Structures of formohydroxamic acid, acetohydroxamic acid and benzohydroxamic acid

The retention of activity by the organic phase during reprocessing of irradiated nuclear fuel
has been studied as a result of solvent degradation into metal coordinating by-products, such as
hydroxamic

acids.42

Baroncelli

and

Grossi

investigated

the

stability

constants

of

benzohydroxamic acid (Figure 4.3, BHA) and metal isotopes present in nuclear fuel waste, 95Zr,
Fe(III), U(VI), U(IV), Th(IV), and Pu(IV). Overwhelmingly, benzohydroxamic acid was shown
to preferentially bind

95

Zr in an acidic environment. In the presence of

95

Zr, a solution of the

highly colored Fe(III)-benzohydroxamic acid complex was slowly decolorized as the Fe(III) was
displaced by

95

Zr. The colored Fe(III) complex was not displaced by any other metal studied.

However, at pH=0, benzohydroxamic acid was also an effective ligand for the coordination of
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Fe(III) and Pu(IV). In the extraction process, investigators believed the formation of hydroxamic
acids soluble in hydrocarbons would lead to the retention of activity in the aqueous phase through
the coordination of isotopes such as

95

Zr and Pu(IV). The study focused on benzohydroxamic

acid, which is insoluble in hydrocarbons, but the data led the authors to conclude that hydroxamic
acids could hold potential as a way to selectively remove specific isotopes during the extraction
process.23,24

The promising chelating behavior of hydroxamic acids with the actinides was mirrored by
hydroxamic acid-containing siderophores, such as ferrichrome and desferrioxamine, which were
investigated for medicinal use.43–52 The development of polyhydroxamic acid ligands provided an
array of chelating ligands for the f-elements. Examples such as BAMPTH,53–55 EDTA-DX,56
CYTROX,57 and many other siderophore derivatives have been shown to be effective chelators of
the f-elements.27,40,54,58,59

As discussed in Chapter 1, the field of polyhydroxamic acid ligands for chelation of the felement is quite promising. However, a lack of consistent data and straightforward synthetic
methods toward purified products has hindered the development of these ligands. However, the
promising nature of these ligands begs for continued research into their development. A project
was carried out to design a series of ligands based on the EDTA framework. By retaining an
ethylenediamine backbone, while manipulating the hydroxamic acid sidearms (length, rigidity), a
better understanding of the topology requirements for selective f-element chelation by a
polyhydroxamic acid ligand could be gained.
In 1971, Motekaitis, Murase and Martell reported the synthesis of N,N’-ethylenediamineN,N’-diacethydroxamic acid (EDTA-DX). Complexation with various divalent metals, Mg(II),
Co(II), Ni(II), Cu(II), and Zn(II) was studied and compared to the constants of the corresponding
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tetraamide EDTA derivative (EDDA) complexes. The stability constants were lower for the
EDTA-DX ligand with each metal, with the largest discrepancy for the square planar Cu(II)
complex (EDTA-DX KML=10.7, EDDA KML=16.2) due to a loss of basic amine interactions.
However, the decrease was markedly smaller for the octahedral metals and an interaction with the
hydroxamic acid amines was suggested.56 The following year, Karlicek and Majer reported the
synthesis of ethylenediamine-N,N,N’,N’-tetraacetohydroxamic acid (EDTAHA) and its
complexes with Fe(III) and Cu(II).

Figure 4.4. Structures of EDTA, EDDA, EDTA-DX, EDTAHA, and EDTPHA.

The main goal of this project was to synthesize a larger version of the EDTHA ligand for
effective chelation of the f-elements. EDTA itself is too small to even encapsulate Fe(III)
(leaving a coordinated water molecule on the iron) and is definitely too small for Ln(III)/An(III).
Consequently,

larger

arms

would

be

necessary
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to

completely

chelate

the

larger

lanthanide/actinide ions. Therefore, the first goal is the synthesis of the EDTPHA (see section
below), which was successful and the stability constants of this ligand with a series of lanthanides
is reported. Ultimately, this project could grow to a series of tetrahydroxamic acid ligands, such
as ethylenediamine-N,N,N’,N’-acethydroxamic acid (EDTHA), ethylenediamine-N,N,N’,N’propionohydroxamic acid (EDTPHA), ethylenediamine-N,N,N’,N’-butyrylhydroxamic acid
(EDTHA), and ethylenediamine-N,N,N’,N’-benzodroxamic acid (EDTHA). This series could
enable a systematic investigation of sidearm length and rigidity and the effect on complex
stability with various metals (partial progress has been made toward completing the series of
ligands). Two methods toward ligand synthesis were investigated, a divergent and convergent
scheme. The target metals studied were La(III), Eu(III), and Lu(III), which allowed better
understanding of trends across the lanthanide series. Stability constants were determined through
potentiometric titrations.

Scheme 4.4: Traditional synthetic routes toward monohydroxamic acids. Typically R in ester = CH3.

4.4 EDTPHA synthesis

Traditional synthetic routes toward monohydroxamic acids involve the conversion of
carboxylic acids, acid chlorides, or esters to the hydroxamate product through reaction with
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hydroxylamine (Scheme 4.4).2,60,61 However, low conversion yields and differentiation (both in
characterization of the reaction progress and ultimately in purification) of the products from the
starting materials, drastically complicate the synthesis of polyhydroxamic acids. Initially, a
divergent approach was investigated for the synthesis of polyhydroxamic acid EDTA derivatives
(Scheme 4.5). This “build-out” method allowed for the use of commercially available starting
materials (e.g. EDTA, hydroxylamine HCl), but required difficult characterization and
purification. The simultaneous conversion of four carboxylic acids to the corresponding
hydroxamic acids proved unsuccessful (consistent with modest yields reported in the literature for
conversions of single carboxylic acids to hydroxamic acids), so consequently, a convergent
approach utilizing protected hydroxamine acids was utilized (Scheme 4.5). This “build-in”
approached required more steps due to the synthesis of the hydroxamate-arm starting materials,
but allowed for more straightforward purification and characterization. This approached
eventually provided a successful route toward the synthesis of EDTPHA, allowing for study of
the stability constants with several metals.
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Scheme 4.5: Divergent and convergent routes toward polyhydroxamic acid EDTA derivatives. The
hydroxylamine moieties of the hydroxamic acids are shown in blue to highlight the different stage at which the
hydroxamic acid is put together.

Divergent “Build-out” Route

Karlicek and Majer employed the traditional divergent route for their reported EDTAHA
ligand.62 The authors reacted ethylenediamine-N,N,N’,N’-tetramethylacetate with a methanolic
solution of hydroxylamine in the presence of strong base. The product was isolated by
precipitation with ether to give a pure, white solid. Several unsuccessful attempts were made to
follow this reported method. The authors used 24 equivalents of base, and hydroxamates are
known to decompose into carboxylates under strongly basic conditions.

107

Scheme 4.6: Aza-Michael addition of methyl acrylate with ethylenediamine. Subsequent reaction with hydroxylamine did not
lead to the hydroxamic acid product, but a mixture of EDTPHA and EDTP.

An aza-Michael addition of an acrylate starting material to an ethylenediamine backbone
allowed for high yielding synthesis of EDTP (ethlyenediaminetatrapropionic acid) derivatives
(Scheme 4.6). Methyl acrylate led to the methyl ester derivative of EDTP, which was then used in
the same reaction scheme as reported by Karlicek and Majer and discussed in the previous
paragraph. Due to the instability of aqueous hydroxylamine solutions, a fresh methanolic solution
was made from hydroxylamine hydrochloride and potassium hydroxide. Cooling the solution
allowed for removal of the resulting potassium chloride by filtration. The filtrate was then reacted
with the methyl ester in the presence of excess potassium hydroxide. Excess hydroxylamine and
potassium hydroxide were used (3eq/NHOH).
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Scheme 4.7: Formation of monohydroxamic acids (top) and possible mixture of products formed during formation of
polyhydroxamic acids (bottom). The starting groups (X), are highlighted in red and the desired hydroxamic acids are
highlighted in blue. Most reactions led to mixtures of the desired hydroxamic acid products as well as starting materials and
carboxylic acids (X=OH) in complex mixtures that

Conversion Problems

The simultaneous conversion of four ester groups to the corresponding hydroxamic acids
proved unsuccessful. Characterization of the reaction was difficult due to a lack of identifying
properties for complete conversion. The traditional iron(III) chloride test, which utilizes the
distinct colors of hydroxamate-Fe(III) complexes for identification, was only able to identify the
presence of hydroxamic acids, but not purity/progress of the reaction. Additionally there is
overlap between carboxylate and hydroxamate features in infrared spectra, meaning IR
spectroscopy is also only useful for confirming the presence of hydroxamic acids, not for
demonstrating complete conversion. A small upfield shift in the 1H NMR of the aliphatic protons
was noted, but peaks representative of the EDTP sodium salt were present as well (Scheme 4.7).
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Collectively, all the evidence suggested that while possible product formation was occurring,
complete conversion was not occurring.

Hydroxamic acids are known to undergo acid and base-catalyzed hydrolysis, similar to the
corresponding amides. With this knowledge, it is not surprising that products in Scheme 4.7
(particularly mixed ones containing carboxylates, i.e., X=OH) are able to form under the
literature procedure. In the case of monohydroxamic acids, while the carboxylic acids may form,
the mixture of products is much simpler and therefore, purification is much more straightforward
(i.e., separating one product from one starting material). However, by attempting this conversion
on multiple arms, many more species with very similar spectral properties as well as polarities are
formed (Scheme 4.7), thereby complicating both characterization and purification.

Figure 4.5: EDTP structure with relevant protons labeled. R = OH (EDTP), ONa (EDTP Na salt), NHOH (EDTPHA).

Optimization Attempts

Several factors in the reaction were varied in an attempt to optimize the product formation and
minimize the side products. Two base/solvent systems were attempted, potassium
hydroxide/methanol and potassium tert-butoxide/tert-butanol. 1H NMR of both systems showed
the growth of the sodium EDTP salt as well as what was believed to be the hydroxamic acid
product (Figure 4.6). The EDTP structure produces three distinct peaks in the 2-3 ppm of 1H
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NMR, in D2O. The ethylenediamine singlet (Figure 4.5, 1) and aliphatic triplet closest to the
backbone (Figure 4.5, 2) do not appear to undergo a large shift between the EDTP sodium salt
and EDTPHA. However, the triplet for the aliphatic protons closest to the changing functional
group (Figure 4.5, 3) does shift between products, allowing for identification of the reaction
products. In Figure 4.6, the peaks in red show the assumed EDTPHA peak, the peaks in blue
show the EDTP sodium salt, and the purple peaks show the unaltered aliphatic triplet (Figure 4.5,
2). This initial study suggested the t-BuOK/t-BuOH system led to a higher ratio of
EDTPHA/EDTP product; however, a mixture was still present. The bulk of the tert-butyl group
was believed to hinder the basic hydrolysis of the hydroxamic acid.

Figure 4.6: 1H NMR of A) EDTP acidic, B) EDTP sodium salt, C) EDTPHA synthesis using NaOH/MeOH, D) EDTPHA
synthesis using t-BuOK/t-BuOH, E) EDTP ethyl ester. All data were collected on a 500 MHz Bruker FT-NMR in D2O. All
reactions stirred at room temperature for 18 h in the presence of 3 eq base/arm. The blue box at 2.3-2.4 ppm demonstrates the
presence of carboxylate arms in multiple synthetic conditions.

In an attempt to limit the hydrolysis products, the length of reaction time, along with amount
of base in the system was varied. Three systems were tested, NaOH/MeOH (4eq base/arm), t-
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BuOK/t-BuOH (4 eq base/arm), and t-BuOK/t-BuOH (2 eq base/arm). Reducing the base amount
to 2 equivalents per arm led to no formation of EDTPHA after 18 hours (Figure 4.7, C). Between
the base/solvent systems, NaOH/MeOH appeared to primarily form EDTPHA after 18 hours in
the presence of 4 eq base/arm (Figure 4.7, A), in comparison to about 60% EDTPHA in the tBuOK/t-BuOH system with the same amount of base (Figure 4.7 B). This contradicts the trend
noted in Figure 4.7, but begins to show some of the difficulties with this system. The low freezing
point of t-BuOH (~23°C) complicates processes such as filtration. For this reason, strict control
over the concentration of the t-BuOH system was difficult and may have led to slight
discrepancies in the results. Despite this, the NaOH/MeOH results with 4 eq base/arm were
promising, so this system was used for the following study, which focused on the effect reaction
time on product formation.

Figure 4.7: 1H NMR of EDTPHA synthesis with varied base concentrations and base/solvent systems. A) NaOH/MeOH, 4 eq
base/arm, B) t-BuOK/t-BuOH, 4 eq base/arm, C) t-BuOK/t-BuOH, 2 eq base/arm. All data were collected on a 500 MHz
Bruker FT-NMR in D2O. All reactions stirred at room temperature for 18 h.
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The length of reaction time was varied in an attempt to isolate EDTPHA before the hydrolysis
products began to form. The length of reaction was varied from 0-24 hours. Along with the
aliphatic peaks, the methyl ester peak was also used for following the reaction progress. Figure
4.8 D appears to show a complete reaction, but the ester product was still present at this point.
Despite this, the data suggests near complete conversion between 1-2 hours, with no formation of
the carboxylic acid product until after 18 hours. This data shows the slow hydrolysis of the
hydroxamic acid group during the basic reaction conditions.

Figure 4.8: 1H NMR of EDTPHA synthesis at different timepoints in NaOH/MeOH (4 eq base/arm) system. A) EDTP sodium
salt, B) 24 hours, C) 18 hours, D) 2 hours, E) 1 hour, F) 0 hours. All data were collected on a 500 MHz Bruker FT-NMR in
D2O.

However, with a polyhydroxamic acid ligand, such as EDTPHA, this data does not fully
represent the reaction products. As can be seen in Figure 4.6, a small shift of one aliphatic peak is
the best indicator of product formation. Changes in mass between the possible products (Table
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4.1) were small and difficult to characterize by MALDI-TOF. Often, due to the extreme basic
conditions, the products could not be identified by MALDI-TOF. Additionally, both
hydroxamates and carboxylates are known to break apart even under the relatively mild
ionization conditions of MALDI-MS (losing hydroxylamine or water, respectively). Thin-layer
chromatography was not useful other than for the identification and loss of the starting material.
Table 4.1: 1H NMR shifts (D2O) and masses of EDTP derivatives. The structure can be seen in Figure 4.4.

R=

A (ppm)

B (ppm)

C (ppm)

Mass (g/mol)

ONa

2.347

2.748

2.612

436.08

OH

2.947

3.549

3.797

348.15

NHO-

2.222

2.741

2.610

404.20

NHOH

2.851

2.656

2.365

408.20

NHOBntBu

2.171

2.533

2.235

993.34

To provide more characteristic differences between starting materials and products, the tertbutyl ester derivative of EDTP was synthesized through the reaction of tert-butyl acrylate and
ethylenediamine. However, this route experienced the same issues as the methyl ester starting
material. An additional attempt to remove the tert-butyl group by trifluoroacetic acid followed by
activation of the hydroxamates by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC) or dicyclohexylcarbodiimide (DCC) and subsequent reaction with hydroxylamine was
hindered by difficulties removing the TFA counteranion, which prevented activation of the
carboxylate.
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Convergent “Build-in” Route

Due to the difficult characterization and purification of the many possible products from the
divergent strategy, a new method was developed to avoid these issues. Several papers published
by Gopalan, Koshti and coworkers discuss the use of O-protected hydroxylamines for the
synthesis of polyhydroxamic acid ligands.63–65 These papers report the use of O-benzyl
hydroxylamine for the synthesis of the ligand, followed by hydrogenation in mild conditions (5%
Pd/C, room temperature/pressure).

Initially, O-benzyl hydroxylamine was bought from a commercial source and reacted with
acryloyl chloride to provide an O-protected hydroxamic acid acrylate for subsequent use in an
aza-Michael addition (Scheme 4.8). Both reactions were straightforward, but required purification
by column chromatography, leading to an overall yield of 14%. The final hydrogenation step was
carried out via balloon hydrogenation with 10% Pd/C in methanol. However, after two weeks,
with constant resupplying of the hydrogen balloon, a mixture of partially-deprotected products (04 benzyl groups) was present. The lengthy hydrogenation conditions began to lead to degradation
of the ligand, rather than removal of the benzyl groups. Additionally, degradation of the Pd
catalyst would definitely occur over two weeks, further diminishing possible reaction.

Scheme 4.8: 1) Synthesis of O-protected hydroxamic acid acrylate followed by 2) aza-Michael addition to
ethylenediamine.
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The removal of multiple benzyl groups simultaneously appeared to be experiencing the same
issues as the divergent route discussed above. A slow reaction time suggested the need for a
protecting group that is cleaved more easily. Gaunt and coworkers reported the effect of
substitution of the benzyl groups on rate of deprotection by hydrogenation in esters (not
hydroxamates). The report stated that the addition of an electron withdrawing group, such as CF3
would slow hydrogenation, while an electron donating group, such as tert-butyl, methyl, or
methoxy, would increase the rate.66 To investigate if this was a viable option for cleaner reaction
conditions, two additional O-benzyl hydroxylamines were synthesized (Scheme 4.9). The route
was first tested by synthesizing O-benzyl hydroxylamine (R = H in Scheme 4.9) and comparing
the product to the commercially available compound.

Scheme 4.9: Synthesis of O-protected hydroxylamine via phthalimide protection of a benzyl bromide, followed
by deprotection of the phthalimide by hydrazine.

Table 4.2: Yields for O-protected hydroxylamine synthesis (Scheme 4.9).

R=

1 Yield (%)

2 Yield (%)

H

83

24

Me

81

86

t-Bu

88-93

90-95

The reaction of a benzyl bromide with N-hydroxyphthalimide was high yielding and only
required precipitation of the product with water. The subsequent deprotection of the phthalimide
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group was carried out by refluxing in chloroform or tetrahydrofuran in the presence of excess
hydrazine. The resulting phthalazine was removed by filtration and the product purified through
extraction. The deprotection step was higher yielding for the methyl and tert-butyl benzyl groups
than for the unsubstituted benzyl. The highest yielding product was the O-tert-butyl benzyl
hydroxylamine, so this was used for subsequent syntheses.

Using the same method shown in Scheme 4.8, an O-tert-butyl benzyl hydroxamic acid acrylate
was formed and added to ethylenediamine using aza-Michael addition. This reaction provided a
slightly better overall yield of 33%. The tert-butyl benzyl protected compound underwent balloon
hydrogenation with 10% Pd/C at room temperature. Although the deprotection of the tertbutylbenzyl protecting group was faster and more complete than that of the unsubstituted benzyl
protecting group, it was still not complete using near-atmospheric pressure balloon
hydrogenation.

Ligand deprotection

Balloon hydrogenation provides an atmosphere of around 60 psi hydrogen. Briefly, an attempt
was made to utilize the departmental Parr hydrogenation system, which should have been capable
of providing a pressures up to ~200 psi. However, the age and lack of care for this instrument left
it in a state of disrepair which did not provide a closed, pressurized system (consequently it both
leaked hydrogen and could occasionally spark). Finally, a system was created which could
provide 1000+ psi of hydrogen. The custom setup utilized a Parr pressurized vessel (Figure 4.9)
to conduct the reaction in. Swagelok connectors and tubing allowed for straightforward and safe
pressurizing of the system. Each reaction was purged multiple times to remove unwanted oxygen.
Once pressurized, the reaction was stirred until complete.
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Figure 4.9: Parr pressurized vessel utilized for high-pressure hydrogenation at room temperature.

The tert-butyl benzyl protected product was hydrogenated with 10% Pd/C in methanol at 1000
psi overnight. After removal of the Pd by filtration through a celite column, the methanol was
evaporated by nitrogen and then a white solid was precipitated by diethyl ether. This white
product was hygroscopic and formed a deep purple solution upon addition of small test quantities
to FeCl3. 1H NMR of this solid suggested a clean product. However, to determine the presence of
unwanted side products, TLC and an FeCl3 stain were used (Figure 4.10). By staining the TLC
plate with FeCl3, the distinct colored Fe(III)-hydroxamic acid complexes could provide a
characterization method. Only the benzyl protected starting material, along with any partially
deprotected products were UV-active. All compounds interacted with the iodide stain, which did
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not indicate the identification of the products. The FeCl3 stain only formed colored spots with
hydroxamic acid-containing products. Characterization of hydroxamic acids by this method has
not previously been reported.

U
V

I

FeCl

Figure 4.10: Characterization of EDTPHA by thin-layer chromatography (TLC). Left) UV light, no stain,
Middle) Iodide stain, Right) FeCl3 stain. S is the protected ligand before hydrogenation and R is the white solid
collected by ether precipitation.

TLC of the white solid from ether precipitation appeared to show two colored spots at the
baseline. However, the 1H NMR only contained one set of peaks in the aliphatic region,
suggesting only one product was present. The two spots in TLC could be from different
conformations of the deprotected ligand caused by hydrogen bonding in solution. Elemental
analysis of this product did not match calculated values. The results showed the possible presence
of various solvent molecules (water, ether, methanol). In an attempt to remove these solvent
molecules, the product was dried in a vacuum oven at 50°C and vacuum over the weekend.
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Unfortunately, this degraded the hydroxamic acid units, most likely due to the added heat. As
shown in Schemes 4.1 and 4.3, hydroxamic acids are capable of undergoing a Lossen
arrangement when heated. The elemental analysis of multiple samples was consistent with
~12.5% decomposition of hydroxamic acid into carboxylic acid while heating under vacuum.

During characterization of the white solid from the initial deprotection, MALDI-TOF was
attempted. While the fully deprotected ligand could not be identified by this method, metal
complexes were able to be formed and identified. The Ln(III) series was coordinated with the
white solid and characterized by MALDI-TOF (Figure 4.11). Lanthanide(III) oxides were mixed
with the product in water and dried on the MALDI plate. A clear trend of coordination is seen
across the series. Initially, the masses appeared to not agree with coordination by EDTPHA.
However, a report from 1969 showed the loss of hydroxylamine during mass spectrometry. 67
With this in mind, the masses observed agree with an ML2 complex and the loss of
hydroxylamine.
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Figure 4.11: MALDI-TOF results of EDTPHA coordination with Ln2O3 series. Nd(III) and Tb(III) not shown
but fit within the trend.

Additionally, the yield of this reaction was unreasonably low (<10%). When the filtrate from
the ether precipitation was characterized, evidence of the fully protected ligand was observed.
When the hydrogenation was carried out for an additional 24 hours, decomposition of the product
began to occur. Increasing the Pd/C catalyst from 10% to 20% did not appear to have an effect on
conversion progress. Due to the strong chelating properties of the hydroxamic acid moiety, all
glassware was acid-washed to remove any residual Fe(III). However, during hydrogenation, the
Pd(0) catalyst is oxidized to Pd(II), before being regenerated as Pd(0). If, as the benzyl groups
were removed, the deprotected hydroxamic acids were capable of chelating the Pd(II) generated
during hydrogenation, this would provide an explanation for the lack of complete deprotection.
Loss of the catalyst during the reaction would prevent further reaction for occurring, thus
explaining why only partial deprotection or low yielding full protection occurred.

By changing the solvent to 30% acetic acid/methanol and increasing the Pd catalyst to 30%,
quantitative deprotection of the ligand was managed after four hours at 300 psi. Removal of the
methanol in vacuo, followed by lyophilization of the product to further remove the acetic acid
results in a viscous, orange oil. Full removal of the acetic acid was not achieved, but through 1H
NMR, determination of the amount of acetic acid present could be achieved. A small ratio of tertbutyl toluene, which was produced by the hydrogenation, was also present in the final product,
but could be quantified by 1H NMR.

4.5 EDTHA, EDTBHA, EDTBnHA Synthesis

To fully investigate the effect of ligand topology on complex stability with various metals,
several additional EDTA derivatives were targeted. The O-tert-butyl hydroxylamine developed
for the EDTPHA synthesis was used for the synthesis of arms for addition to the ethylenediamine
backbone. For EDTHA, chloroacetyl chloride was reacted with the O-protected hydroxylamine to
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give chloroacetyl-O-tert-butylbenzyl-hydroxamic acid in excellent yield (96%). Chlorobutyrl
chloride underwent the same reaction to produce chlorobutyryl-O-tert-butylbenzyl hydroxamic
acid in quantitative yield. Both products were white, crystalline solids. The same reaction was
used to produce 4-chloromethyl benzo-O-tert-butyl hydroxamic acid from 4-chloromethyl benzyl
chloride.

Scheme 4.10: Synthesis of arms containing O-tert butyl benzyl protected hydroxamic acids for (top to bottom)
EDTHA, EDTPHA, EDTBHA, EDTBnHA.

The subsequent nucleophilic substitution of the alkyl chloride with the ethylenediamine
backbone was the major roadblock for this route. To combat the low reactivity of the Cl- ion,
catalytic potassium iodide was added to the reaction. This addition led to a complicated mixture
of compounds, including starting material. The oxidation of hydroxamic acids to nitrous acid by
iodine, followed by hydrolysis to the carboxylic acid (Scheme 4.11) was reported by Kobashi and
coworkers.68 This report suggests that rather than speeding up reaction with ethylenediamine, the
potassium iodide leads to the formation of unwanted products through the decomposition of the
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starting material. In future work similar reactions could be performed using a bromide source to
catalyze the SN2 reactions of the relatively inert chloride.

Scheme 4.11: Oxidation of hydroxamic acid by iodine, followed by hydrolysis to a carboxylic acid. 68

Several attempts to change the reaction system for successful synthesis of EDTHA and
EDTBHA were made. The acetyl arm was reacted with ethylenediamine in the presence of excess
sodium carbonate for over a month. Evidence of product formation was seen by TLC; however
the product could not be isolated and starting material was still present. Using triethylamine as the
base instead led to a messier mixture of products and no evidence of product formation. The butyl
arm appeared to cyclize during some synthesis attempts, preventing addition to the backbone.

The major issue with these reaction conditions was the possible formation of ligands with
various amounts of arms. The desired ligand would have contained four arms, however, MALDITOF indicated the presence of the three-armed and five-armed products. To combat this problem,
primarily the significant amount of under-reacted three-arm ligand, excess stoichiometric
equivalents of the arm synthon were added to the reaction. Characterization did not indicate any
improvement in terms of the percentage of desired product in the reaction mixture.

EDTBnHA was successfully synthesized by reacting the benzyl arm with ethylenediamine in
the presence of sodium carbonate for one month. The product was isolated by recrystallization as
a white solid. Deprotection of the hydroxamic acid groups was attempted by high-pressure
hydrogenation in methanol with 10% Pd/C. After 18 hours, no deprotection was observed.
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Solubility in methanol was limited, so the solvent was changed to ethanol. The change of solvent
did not improve deprotection. Increasing the length of deprotection to over 48 hours did not lead
to any change. When the deprotection was performed in 30% acetic acid/ethanol for four hours,
evidence of deprotection was observed. However, full deprotection required a longer reaction
time.

4.6: Stability constant determination

Potentiometric titrations were performed to study of the effect of changing the carboxylates in
EDTP to hydroxamates (EDTPHA). In all cases titrations are performed by dissolving species
(either a ligand or a ligand and a metal ion at various ratios) in buffered acidic media and then
titrating with base. The potential of the solution is monitored with a pH electrode and is plotted
as a function of the volume of base added. A model is generated to account for the protons
arising from ligands deprotonating, metal-aquo ligands deprotonating, etc., and the model is
refined to match the data.

From ligand titrations, the pKa of each proton (referred to as

protonation constants below) can be determinedwithin the pH range of the titration, and metalligand titrations yield a stability constant, similar to a Ka from simpler systems but accounting for
the number of metal ions, ligands, and protons.

Protonation constants allow for understanding of the acidic nature of these ligands. Stability
constants with La(III), Eu(III) and Lu(III) were determined to study the formation of complexes
with EDTP and EDTPHA. Stability constants measure the extent of formation of a complex in
relation to other components of the system at equilibrium. Higher stability constants represent a
higher percentage of that complex as one of many possible species in the system.
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Protonation constants

The first titrations performed were to determine the protonation constants of EDTA and the
formation constants for EDTA-Fe(III). These were done to show agreement with literature values
and validate the methods being used. The blind fit of the data matched the literature values well
enough to not require subsequent manipulation of the data. EDTP protonation constants were
determined and compared to literature values.69,70 The values for this work were corrected for
activity using the Davies equation (Equation 1), where γ is the activity coefficient, z is the charge
of the complex and I is the ionic strength of the system. Without the activity correction, the
values were comparable to the literature values. Corrections were performed to account for the
ionic strength of the system. Corrections lowered the values slightly; however, they are still
within an acceptable range. The protonation constants are defined in Equations 2-11.

√𝐼
1+√𝐼

−𝐿𝑜𝑔(𝛾) = 0.51𝑧 (

− 0.30𝐼)

(1)

EDTP has six protons; however in the pH range of the system, only five protonation
constants could be determined. The first four values (logK HL-logKH4L) represent dissociation of
the protons from the carboxylate groups and the last two values (logKH5L and logKH6L) represent
dissociation of the ammonium backbone protons.71 The protonation constants fall within expected
values for polycarboxylate ligands, such as EDTA.

Titration data for EDTPHA (Figure 4.5) has not been published. The closest literature
comparison is the 1972 report of EDTAHA (Figure 4.4) by Karlicek and Majer. 62 These values
were used to initially build a model to compare the EDTPHA titration data to. Refinement of the
values to match the data led to the values listed in Table 4.2. The ligand concentration was varied
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(0.5-1.2 mM) to confirm the values. These values were used for modelling the metal
complexation titrations with La(III), Eu(III), and Lu(III).
H6L6+ ↔ H5L5+ + H+

(2)

+

H5L ↔ H4L + H

(3)

H4L4+ ↔ H3L3+ + H+

(4)

H3L3+ ↔ H2L2+ + H+

(5)

H2L ↔ HL + H

(6)

HL ↔ L + H

(7)

L ↔ L- + H+

(8)

5+

4+

2+

+

+

+

+

L- ↔ L2- + H+

(9)

L ↔L +H

(10)

L ↔L +H

(11)

23-

34-

+
+

Table 4.3: The protonation constants of EDTP and EDTPHA (I = 0.1 M NaClO4, T = 25°C).
EDTA
EDTP
EDTAHA
LogKn
L3-

Literature71*

Literature70,71

Literature69

This work

Literature62

EDTPHA
This work

10.21±0.04

9.74

9.43±0.04

8.80±0.5

11.1±0.1

11.5±0.05

2-

6.20±0.04

6.25

6.12±0.06

5.91±0.4

10.6±0.1

10.4±0.1

-

L

2.77±0.04

4.29

4.17±0.07

4.00±0.3

7.23±0.02

9.33±0.1

L

2.02±0.05

3.30

3.40±0.07

3.27±0.3

6.67±0.03

10.9±0.1

HL+

1.31±0.10

2.98

2.90±0.07

2.72±0.2

6.05±0.05

9.89±0.2

5.55±0.05

9.09±0.1

L

2+

H2L

3+

8.89±0.2

4+

H4L

9.53±0.1

H5L5+

7.75±0.3

6+

7.55±0.2

H3L

H6L
All data determined by potentiometric titrations. *0.1 M KNO3

Karlicek and Majer only reported six protons, the four hydroxamate (OH) groups and the two
backbone ammonium protons. This set of protons was initially used but did not allow the model
to accurately predict the behavior of the data, as can be seen in Figure 4.13, which shows the
observed data (blue line) versus the calculated data (red line) with six protons. Figure 4.14 shows
the fit of the data (blue line) to the model (red line) with ten protons and refinement of the values.
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The model requires the assumption that the hydroxamate amino groups are all protonated in
H6L6+ (Figure 4.12). The resonance of the hydroxamate anion (Scheme 4.2) explains why the first
eight protonation constants are nearly the same. The constants most likely represent an average of
the loss of the two protons from each hydroxamate and the effect of the resonance structures. The
speciation diagram of the base titration of EDTPHA is shown in Figure 4.15. The diagram shows
the relatively low formation of L-, HL+, H3L3+, and H5L5+. further confirming the nearly
simultaneous loss of both protons from each hydroxamate group. The data fits the 10H model
across varying ligand and acid concentrations, verifying the validity of the model (Figure 4.16).

Figure 4.12: Example suggested protonation states for EDTPHA ligand in 10 proton model (Table 4.3).

Figure 4.13. Calculated (red) and observed (blue) pH of base titration of EDTPHA in 0.1 M NaClO 4 with six
protons in the model.
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Figure 4.14. Calculated (red) and observed (blue) pH range of base titration of EDTPHA in 0.1 M NaClO 4 with
ten protons in the model.

Figure 4.15. Speciation diagram for base titration of EDTPHA. Only a pH range of 7-11 (black line) is shown.

Comparison of the stability constants of coordination with La(III), Eu(III) and Lu(III)
allowed for direction comparison of the chelation ability of EDTP and EDTPHA. The choice of
metals also allowed for understanding of the general trend across the lanthanide series. The use of
perchlorate salts of the metals avoided the presence of coordinating anions in the system.
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However, the EDTPHA solution did have acetic acid present in a high enough concentration (a
consequence of the final deprotection and the ligand’s decomposition under sufficient vacuum
and heat to remove all the acetic acid) that it had to be accounted for in the model. Fortunately,
the acetic acid-Ln(III) coordination did not compete with the ligand.

Figure 4.16. EDTPHA protonation trials with varying conditions. (A) EDTPHA (0.475 mM), AcOH (7.125 mM),
H+ (15.4 mM), titrate 30 mL 0.01 M NaOH. (B) EDTPHA (0.475 mM), AcOH (7.125 mM), H + (11.25 mM),
titrate 16 mL 0.01 M NaOH. (C) EDTPHA (1.9 mM), AcOH (45 mM), H+ (28.5 mM), titrate 45 mL 0.01 M
NaOH.
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Table 4.4. Stability constants for EDTP with La(III), Eu(III), and Lu(III) (I = 0.1 M NaClO4).
Logβ
La(III)
Eu(III)
Lu(III)
M(OH)2+
-8.641
-7.76
-7.61
M(OH)2+

-11.61

-15.8

-11.6

1

-21.4

-14.5

M(OH)3

-20.3

-

ML

11.6±0.9

10.3±1.0

MLH

16.4±1.6

19.0±0.9

23.4±2.1

14.02

14.32

14.02

25.2±2.1

25.2±1.5

27.6±0.9

MLH2

19.4
MLH3

2

33.8±0.6
22.6

19.7

2

27.9±1.4

2

22.7

2

This work

19.1

This work

2

29.7±2.7
22.3

This work

This work

2

ML2

20.9±0.8

15.6±0.8

21.0±0.2

This work

ML2H

26.7±2.0

24.0±1.1

29.3±1.1

This work

29.6±2.6

33.4±0.6

35.6±2.9

This work

ML2H2
72

(1) LLNL Database. (2) Ref 69 (I = 0.1 M NaClO4)

The stability constants of EDTP with the lanthanide series have been reported. 69 However,
the authors only reported the existence of ML species and not possible ML2 species. Additionally,
the authors ignored the lanthanide hydrolysis products, despite the pH range of 3-12, which could
allow for the formation of insoluble hydroxide complexes. Modeling the data with the reported
ML, MLH, MLH2, and MLH3 complexes did not lead to a good fit. However, the suggested
complex structure from Hietapelto and coworkers (Figure 4.17) leaves room for the formation of
the ML2 species. Addition of ML2 species (including ML, MLH, and ML2H) and refining the data
allowed for fitting of the data and determination of the stability constants.

The stability constants determined in this work are drastically different from the reported
values, most likely due to the inclusion of the ML2 species. Without identification of the species
during titration, these constants cannot be considered definitive; however, the model provides the
best fit of the data, suggesting a possible speciation of the system. The large error for MLH2 and
MLH3 are due to the low relative formation of these complexes in the system. The primary
complex formed is the ML2 complex.
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Figure 4.17. Suggested ML structure of EDTP-Ln(III) complex.69

Modeling the speciation of EDTPHA with the lanthanides was much more complicated.
Karlicek and Majer reported stability constants of EDTAHA with Fe(III) and Cu(II). 62 Other
polyhydroxamate ligands have been studied with other metals, including La(III), Th(IV) and
U(VI).54,63,73 Figure 1.3 shows some of the reported polyhydroxamate ligands that have been
reported. However, there have not been any stability constants for EDTPHA reported. The model
for the studied system was built using the constants from Table 4.4 as a starting point.
Additionally, constants reported for H4CDTMAHA (Figure 1.3, VI) were considered. The authors
reported possible MLH4 with Th(IV) and M2L2H4 with Fe(III).73

According to the modeled data, the metals remain coordinated by acetic acid until around pH
6, when the ligand begins to coordinate them. Between pH 6.4 and 7.3, the primary complex is
MLH8, then MLH6 (pH 7.3-8.5), then MLH4 (pH 9.4-9.2), then MLH2 (pH 9.2-10.3) and finally
ML2 (pH 10.3+). The major complexes follow the dissociation of the protons from the
hydroxamate arms. Definitive determination of the speciation would require mass spectrometry to
understand what complexes are present in the system.

132

Table 4.5. Stability constants for EDTPHA with La(III), Eu(III), and Lu(III)
(I = 0.1 M NaClO4).
Logβ
-

ML

MLH

La(III)

Eu(III)

Lu(III)

15.0±0.03

18.1±1.9

15.5±0.08

26.3±1.8

27.9±2.2

26.2±0.7

+

38.3±1.3

38.3±1.1

37.3±0.2

MLH3

+2

47.4±1.3

47.7±0.9

47.0±0.3

MLH4+3

56.6±0.4

56.8±0.4

56.3±0.2

+4

64.4±0.001

65.0±0.6

65.0±0.3

+5

73.6±0.2

73.8±0.07

73.8±0.2

MLH7

+6

81.2±0.3

81.2±0.4

81.6±0.2

LMH8+7

88.3±0.5

88.6±0.4

88.6±0.3

23.7±0.8

26.2±1.4

21.9±1.7

MLH2

MLH5
MLH6

-5

ML2

-4

ML2H

32.9±1.3

32.1±1.3

31.6±0.3

ML2H2

-3

44.5±0.6

45.1±1.6

42.5±0.9

ML2H3-2

54.7±0.7

56.6±1.2

53.3±0.6

ML2H4

-

64.8±0.2

66.0±1.1

63.5±0.3

M2L2H2

56.1±0.1

56.9±0.7

56.7±0.4

AcOH

4.78±0.04

4.67±0.02

4.73±0.07

MAcO+2

1.851

1.851

1.851

M(AcO)2+

5.011

5.011

5.011

8.82±0.7

9.18±1.1

10.2±1.2

M(AcO)3
(1) NIST Database 46.

74

The best comparison of the chelating ability of EDTP and EDTPHA is the LH2 stability
constants. The logβML2 values for EDTPHA are higher than the corresponding EDTP constants,
signifying stronger complex formation by EDTPHA. The metal complexation undergoes the same
trend as EDTP, with the metal fully coordinated by the ligand by about pH 7. The primary
complexes cycle through MLH8, MLH6, MLH4, MLH3, MLH2 and finally ML2.
The logβML constants are also higher for EDTPHA than EDTP. The EDTPHA values are in
the range for what has been reported for EDTA with d-block metals and lanthanides
(logβML~18).74 For the best possible comparison, titrations of EDTAHA with the lanthanides
would be necessary. These titrations would allow for an understanding of not only the effect of
including the hydroxamate groups, but also extending the arms by one carbon. However, the
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reported data for EDTPHA provides an insight into the promising chelating ability of this
decadentate ligand. Final refinements of the data are underway and will give more insight into the
EDTPHA coordination system.

4.7. Conclusions

Ligand design for the f-elements has been driven by the need for highly selective ligands
capable of forming stable complexes in complex environments. The unique chemistry of the
hydroxamic acid functional group, as seen in the interaction of siderophores with environmental
Fe(III), led to attempts to utilize them in the design of f-element ligands. The bidentate nature of
hydroxamic acids allowed for coordination of larger metals with high coordination numbers (e.g.
f-elements). Many literature examples exist studying the effectiveness of mono- and
polyhydroxamic acid ligands for coordination of the lanthanides and actinides. While there is
much promise in the reports, the big downfalls of hydroxamic acids are the difficult synthesis,
characterization and purification of the group. This downfall required the development of a
straightforward route toward the synthesis of polyhydroxamic acid ligands.

A route toward the synthesis of polyhydroxamic acid ligands utilizing O-protected
hydroxylamines and acrylate starting materials has been developed. The use of O-protected
hydroxylamines circumvents the difficult characterization and purification of traditional
hydroxamic acid synthesis. This route was used to synthesize a tetrahydroxamic acid EDTA
derivative, EDTPHA. The tetrabenzyl-protected ligand was synthesized through the aza-Michael
addition of O-protected hydroxamic acid acrylate and ethylenediamine. The benzyl groups were
removed under pressure (300 psi) in the presence of Pd/C and acetic acid.
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Potentiometric titrations were used to study and compare the solution thermodynamics of
EDTPHA and the carboxylate derivative, EDTP. Stability constants were determined for both
ligands with La(III), Eu(III), and Lu(III). For both ligands, the data suggests the dominant metal
complex in solution is the ML2 complex. Overall, the stability constants were higher for
EDTPHA than EDTP, suggesting a positive impact on complex stability from the addition of the
hydroxamic acid functional group. The stability constants of EDTPHA with the lanthanides that
were studied were similar to EDTA, while the EDTP constants were several orders of magnitude
lower than EDTA. These promising results suggest that EDTPHA could be equally as effective as
EDTA for coordination of the f-elements. The slightly lower values of EDTPHA suggest that the
propyl hydroxamate arms may have created a binding pocket too large for the lanthanides. In this
case, a smaller ligand, EDTHA, must be studied to better understand the topology effects on
coordination of the target metals. With optimization, this ligand design could hold potential for
the use in the selective coordination of the lanthanide and actinides.

4.8. Future directions

Ligand design

For better understanding of the effects of the inclusion of hydroxamic acids into an
ethylenediamine backbone, a full series of EDTA derivatives must be studied. EDTA is too small
for Fe(III) and allows for the coordination of a solvent molecule with the metal core when fully
coordinated. When the target metal is the larger f-elements, the smaller ligand size becomes a
major issue for complex stability. While the inclusion of hydroxamic acids will increase the
coordination sites of the ligand, from hexadentate to decadentate, they would be unable to fully
coordinate a large metallic core if the ligand backbone is too small. The ultimate goal for the
project is to study the effect of the arm length of the ligand on the complex stability with the f-
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elements. Future ligands to be synthesized should include the acetyl arm (EDTHA), butyl arm
(EDTBHA) and benzyl arm (EDTBnHA) for study of ligand preorganization as well as arm
length. The hydroxamic acid-containing arms have all been synthesized in high yield. However,
the final addition of the arms to the ethylenediamine backbone was not accomplished. Once this
chemistry has been worked out, a full series of ligands will be able to be studied. Additionally,
the ligands should be compared to their carboxylate counterparts, EDTA, EDTBA, and EDTBnA
to further understand the effects of the hydroxamic acid arms.

The straightforward and highly successful use of the acrylate starting material used for the
synthesis of EDTPHA in and aza-Michael addition for the synthesis of a polyhydroxamic acid
ligand holds a lot of potential for the creation of novel polyhydroxamic acid ligands. For
example, initial attempts were made to add the acrylate arm to 1,4,7,10-tetraazacyclododecane
(cyclen). This synthesis has been published,57 but no work with metals was published. The
preorganized backbone might provide a positive impact on the coordination of metals due to the
lower entropic requirement of coordination. The acrylate arm could be added to a variety of
amines through the aza-Michael addition reaction, leading to a new group of polyhydroxamic
acids for study with the f-elements.

Solution thermodynamics

The reported titration data was determined by potentiometric titrations. The suggested models
were determined computationally. For further confirmation of the speciation of the systems, mass
spectrometry must be carried out at varying pH and concentrations. This study will determine
which species are present at different points of the titration. Additionally, the stability constants
with other metals, such as thorium(IV) and plutonium(IV) would allow for further investigation
of the effectiveness of EDTPHA for the coordination of the f-elements. The distribution constants
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of metals with EDTPHA would give further insight into the complex stability of the ligand with
various metals in competitive environments. This experiment would also show the effectiveness
of the ligand at separating metals in liquid-liquid extraction.

Once synthesized, the full series of ligands would need to be studied with all metals in order
to optimize the ligand design. Each polycarboxylate and polyhydroxamate ligand would need to
be compared to fully understand the topology effects of the inclusion of the hydroxamic acid
group.
4.9. Experimental – Synthetic methods
Chemicals: N-hydroxyphthalimide and triethylamine were obtained from Chem-Impex. 4-tButylbenzyl bromide was obtained from Oakwood Chemicals. Hydrazine monohydrate and
acryloyl chloride were obtained from Beantown Chemicals. Chloroacetyl chloride was obtained
from Alfa Aesar. 4-Chlorobutyryl chloride was obtained from EMD Millipore. 4-Chloromethyl
benzoyl chloride was obtained from TCI. All solvents were obtained from BDH. All chemicals
were used without further purification.

Scheme 4.12. Synthesis of O-tert butyl benzyl hydroxamic acid.

Synthesis of O-tert butyl benzyl hydroxamic acid: (1) Minimal N,N-dimethylformamide (300
mL) was used to dissolve N-hydroxylphthalimide (1 eq, 24.4 g) in a round-bottom flask, resulting
in a yellow solution. Slowly, triethylamine (1 eq, 20.9 mL) was added to the reaction, which
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turned the reaction mixture dark red. 4-t-butylbenzyl bromide (1 eq, 27.5 mL) was then added.
After less than a minute, the reaction began to lighten, as solid began to form. The reaction was
stirred at room temperature under ambient conditions. After 48 hours, enough solid was present to
give the reaction an orange hue. The volume was doubled with deionized water, precipitating the
product as a white solid, which was collected by vacuum and dried (43.4 g, 94%). 1H NMR (500
MHz, DMSO): 7.19-7.17 δ (d, J = 10.25 Hz, 2 H), 6.86-6.84 δ (d, J = 10.25, 2 H), 3.73 δ (s, 2 H),
1.50 δ (s, 9 H). 13C NMR (500 MHz, DMSO): 156.6 δ, 156.3 δ, 129.5 δ, 129.4 δ, 129.0 δ, 128.9
δ, 126.4 δ, 126.3 δ, 115.5 δ, 67.0 δ, 45.9 δ, 44.6 δ, 28.4 δ, 27.7 δ.

(2) Hydrazine monohydrate (10 eq, 130 mL) was slowly added to a solution of 1 (1 eq, 41.4 g) in
chloroform (400 mL). The reaction mixture was stirred under reflux. Hydrazine was added every
eight hours, three times for a total of 30 eq. After 24 hours, the reaction was cooled and the
product extracted into dichloromethane three times, then dried over anhydrous sodium sulfate.
The solvent was removed under reduced pressure, resulting in a viscous, colorless liquid (23.5 g,
98%). 1H NMR (500 MHz, DMSO): 7.37-7.33 δ (t, J = 8.31 Hz, 2H), 7.26-7.22 δ (t, J = 8.31),
4.53 δ (s, 2H), 1.28 δ (s, 9H). 13C NMR (500 MHz, DMSO): 150.28 δ, 135.71 δ, 128.31 δ, 125.35
δ, 77.18 δ, 34.69 δ, 31.63 δ.

Scheme 4.13. EDTPHA synthesis.
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Synthesis of EDTAHA: (3) Synthesis: 2 (1 eq, 17.9 g) and sodium carbonate (2 eq, 21.1 g) were
cooled to 0°C in dichloromethane (200 mL). Chloroacetyl chloride (1 eq, 7.9 mL) was slowly
added by addition funnel. More dichloromethane was added to aid stirring as a white solid began
to form. The reaction was stirred at room temperature under ambient conditions for 4 hours. The
reaction was filtered and the solvent was removed from the filtrate under reduced pressure,
resulting in a white solid. The product was recrystallized in methanol, producing colorless,
crystalline plates. (24.4 g, 96%). 1H NMR (500 MHz, DMSO): 1.280 (s, 9.5 H), 3.964 (s, 1.7 H),
4.777 (s, 2.0 H), 7.317-7.333 (d, 1.9 H), 7.403-7.419 (d, 2.0 H), 11.470 (0.94 H). 13C NMR (500
MHz, DMSO): CNMR (500 MHz, DMSO): 31.11, 34.35, 40.33, 76.67, 125.15, 128.85, 132.72,
150.91, 163.18.

Scheme 4.14. EDTPHA synthesis.

Synthesis of EDTPHA: (5) 2 (1 eq, 3.1 g), sodium carbonate (2 eq, 3.6 g), and dichloromethane
(100 mL) were cooled to 0°C in an acid-washed round-bottom flask. Acryloyl chloride (1 eq, 1.4
mL) was added over 30 minutes by addition funnel. More dichloromethane was added to aid
stirring after the immediate formation of a white solid. The reaction was stirred at room
temperature for 24 hours. The reaction mixture was then purified by extraction. The product was
extracted into dichloromethane three times and dried over anhydrous sodium sulfate. The product
was further purified through flash column chromatography (0-5% methanol/dichloromethane).
Solvent was removed under reduced pressure, resulting in a pale, yellow oil (2.3 g, 58%). 1H
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NMR (500 MHz, CDCl3): 1.310 (s, 9.15 H), 4.911 (br s, 1.7 H), 5.677 (br s, 0.77 H), 6.002 (br s,
0.50 H), 6.331-6.370 (br d, 0.82 H), 7.309-7.323 (d, 1.9 H), 7.383-7.400 (d, 2.0 H).

(6) 5 (4.1 eq, 10.5 g) and ethylenediamine (1 eq, 0.73 mL) were dissolved in minimal
tetrahydrofuran (100 mL) in an acid-washed round-bottom flask. The reaction was stirred under
reflux for 72 hours. After cooling, the solvent was removed under reduced pressure to give a
yellow oil. The product was purified through column chromatography. The pure product was a
white, crystalline solid (3.6 g, 31% yield). 1H NMR (500 MHz, DMSO): 7.27-7.26 δ (d, J = 8.25
Hz, 1.4 H), 7.10-7.09 δ (d, J = 8.25 Hz, 1.4 Hz), 3.18 δ (s, 4 H), 2.66-2.63 δ (t, J = 7.50 Hz, 8 H),
2.43 δ (s, 4 H), 2.26 δ (s, 2.2 H), 2.11-2.08 δ (t, J = 7.50 Hz, 8 H), 1.91 δ (s, 28 H), 1.26 δ (s, 7
H). 13C NMR (500 MHz, DMSO): 172.5 δ, 168.7 δ, 134.6 δ, 129.0 δ, 125.4 δ, 49.9 δ, 49.1 δ, 31.7
δ, 30.6 δ, 21.6 δ, 20.9 δ.

Scheme 4.15. EDTBHA synthesis.

Synthesis of EDTBHA: (7) 2 (1 eq, 12.6 g), sodium carbonate (2 eq, 14.9 g), and
dichloromethane (300 mL) were cooled to 0°C in an acid-washed round-bottom flask. 4Chlorobutyryl chloride (1 eq, 9.9 g) was added. More dichloromethane was added to aid stirring
after the immediate formation of a white solid. The reaction was stirred at room temperature for
24 hours. Solvent was removed in vacuo, resulting in a white solid (20.0 g, quant.). 1H NMR (500
MHz, DMSO): 11.02 δ (s, 1 H), 7.40-7.39 (d, J = 7.98 Hz, 2 H), 7.32-7.30 δ (d, J = 7.98 Hz, 2
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H), 4.74 δ (s, 2 H), 3.62-3.59 δ (t, J = 6.60 Hz, 2 H), 2.12-2.10 δ (t, J = 6.60 Hz, 2 H), 1.96-1.92 δ
(m, J = 6.94 Hz, 2 H), 1.28 δ (s, 9 H).

Scheme 4.16. EDTBnHA synthesis.

Synthesis of EDTBnHA: (9) 2 (1 eq, 10.8 g)was cooled to 0°C in a mixture of dichloromethane
(150 mL) and Na2CO3 (2 eq, 12.8 g). While the mixture was stirring, 4-chloromethylbenzoyl
chloride (1 eq, 11.4 g) in dichloromethane (100 mL) was slowly added dropwise. A white solid
formed immediately, requiring more dichloromethane for stirring. The reaction was stirred at
room temperature overnight. The solid was removed by filtration and the solvent removed from
the filtrate under reduced vacuum. The resulting white solid was recrystallized in
dichloromethane. The final product was a crystalline, white solid. 1H NMR (500 MHz, DMSO):
7.77-7.75 δ (d, J = 9.13 Hz, 2 H), 7.53-7.52 δ (d, J = 9.13 Hz, 2 H), 7.43-7.41 δ (d, J = 9.13 Hz,
2 H), 7.38-7.37 δ (d, J = 9.13 Hz, 2 H), 4.89 δ (s, 2 H), 4.80 δ (s, 2 H), 1.28 δ (s, 9 H). 13C NMR
(500 MHz, DMSO): 150.8 δ, 141.1 δ, 132.9 δ, 132.2 δ, 128.9 δ, 127.5 δ, 76.8 δ, 45.4 δ, 34.3 δ,
31.1 δ.
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4.8. Experimental: Potentiometric titrations

Potentiometric titrations

General: All titrations were performed with an 836 Titrando equipped with an 800 Dosino
autotitrator. An Orion 8102BNUWP Ross Ultra pH electrode was used to measure the change in
potential during titrations. A NIST standardized 0.01 M NaOH solution was used. This solution
was used to standardize 0.01 M HClO4 solutions made from the dilution of a 1 M solution from
Fluka. All titrations were performed in a vessel jacketed by a water bath set to 25°C. The ionic
strength was kept constant with 0.1 M NaClO4 (EMD Chemicals). Protonation constants were
determined by titrating a solution of the ligand in NaClO4 with NaOH up to pH 12. The ligand
concentrations were varied (0.5-1.5 mM) to further confirm the constants. Before each titration,
the electrode was calibrated by an acid-base titration with standardized 0.01 M NaClO4 and 0.01
M NaOH. The E0 and slope factor values were obtained by analyzing the calibration data with
GLEE3. Measurements were recorded every 0.15 mL and the probe equilibration time was 360
sec for the calibrations and 900 sec for the experiments. The models were built using HySS and
literature values. All data was compared and refined with Hyperquad.75 All metal solutions were
made from perchlorate salts and were 0.03 M in 0.01 M HClO4. The logKOH value was set to 13.997 for all titrations.

Electrode calibration: 2 mL of 0.01 M HClO4 in 28 mL 0.1 M NaClO4 was titrated with 4 mL
0.01 M NaOH. The electrode equilibration time was set to 360 sec. The E0 value was determined
by analyzing the data with GLEE3.76

EDTA titrations: A 0.03 M EDTA solution was made by dissolving disodium EDTA (BDH,
2.2334 g) in 200 mL 0.1 M NaClO4. A 0.03 M Fe(ClO4)3 solution was made by dissolving
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Fe(ClO4)3•H2O (Beantown Chemical, 2.7734 g) in 200 mL 0.01 M HClO4. Protonation constants
were determined by base titrations of EDTA (0.5-1.5 mM) from pH 3-10. Stability constants for
EDTA-Fe(III) complexes were determined by base titrations of mixtures of 1:1, 1:2, and 1:3 M:L.
There were carried out from pH 3-10.

EDTP titrations: A 0.03 M EDTP solution was made by dissolving EDTPNa4(H2O)2 (2.834 g) in
200 mL 0.1 M NaClO4. To cover a pH range of 4-10, 0.01 M HClO4 was added to the beginning
of the titration to lower the pH. Stability constants for La(III), Eu(III) and Lu(III) and EDTP were
all determined by base titrations of mixtures of 1:1, 1:2, and 1:3 M:L.

EDTPHA titrations: A 0.016 M EDTPHA solution was made by dissolving EDTPHA (0.162 g)
in 25 mL 0.01 M HClO4. Stability constants for La(III), Eu(III) and Lu(III) and EDTP were all
determined by base titrations of mixtures of 1:1, 1:2, and 1:3 M:L.
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CHAPTER FIVE
FUTURE DIRECTIONS
Future Directions

Each project discussed in this work has been left open for future possibilities. The
azamacrocyclic ligands are in need of more rigidity in the backbone to increase binding
capabilities of the uranyl ion. Now that the monomer synthesis for the inclusion of hydroxamates
in cyclopeptoid backbones has been worked through, large, complex polyhydroxamate ligands
can be synthesized for the coordination of the tetravalent actinides. Additionally, the inclusion of
catechols in cyclopeptoid backbones has been shown to be possible. With optimization,
polycatecholate ligands can also be synthesized this way. Finally, a very promising
tetrahydroxamate ligand, EDTPHA was synthesized and studied with several Ln(III) metals by
potentiometric titrations. These preliminary studies must be expanded on to fully determine the
speciation of the system at varying pH. Additional titrations with larger metals, such as Th(IV)
and Pu(IV) would allow for understanding of how the decadentate ligand may interact with
metals of higher coordination numbers. The efficiency of this ligand in the separation of the felements could be studied through the determination of the distribution coefficients of various
metals. For the best results, the full series of ligands, EDTAHA, EDTPHA, EDTBHA and
EDTBnHA must be studied and compared to their corresponding carboxylates to determine the
effects of the hydroxamate inclusion and binding pocket size changes.

I sincerely hope to see this work contribute to the future of the field of ligand design for the felements.
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Appendix A
Macrocyclic ligand NMR Data
Data presented here is discussed in Chapter two.
Figure A.1. 1,2-ethanediylbis(oxy-2,1-ethanedyl) bis(4-methylbenzenesulfonate) (500 MHz, 1H
NMR, DMSO).
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Figure A.2. 1,2-ethanediylbis(oxy-2,1-ethanedyl) bis(4-methylbenzenesulfonate) (500 MHz, 13C
NMR, DMSO).
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Figure A.3. 1,10-dibutane diamine-1,10-diaza-18-crown-6 (500 MHz, 1H NMR, DMSO).
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Figure A.4. 1,10-dibutane diamine-1,10-diaza-18-crown-6 (500 MHz, 1H NMR, DMSO).
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Appendix B
Cyclopeptoid monomer NMR data
Data presented here is discussed in Chapter three.
Figure B.1. Methyl 4-(aminomethyl)benzoate (500 MHz, 1H NMR, D2O).
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Figure B.2. Methyl 4-(aminomethyl)benzoate (500 MHz, 13C NMR, D2O).
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Figure B.3. Ethyl 4-(aminomethyl)benzoate (500 MHz, 1H NMR, D2O).
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Figure B.4. NHS-activated 2,3-dihydroxybenzoic acid (500 MHz, 1H NMR, DMSO).
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Figure B.5. Phthalimide-protected β-alanine (500 MHz, 1H NMR, CDCl3).
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Figure B.6. Phthalimide-protected γ-GABA (500 MHz, 1H NMR, CDCl3).
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Appendix C
EDTA hydroxamate derivatives NMR data
Data presented here is discussed in Chapter four.
Figure C.1. Phth-NH-O-Bn-t-Bu (500 MHz, 1H NMR, CDCl3).
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Figure C.2. Phth-NH-O-Bn-t-Bu (500 MHz, 13C NMR, CDCl3).
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Figure C.3. O-tert-butylhydroxylamine (500 MHz, 1H NMR, CDCl3).
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Figure C.4. O-tert-butylhydroxylamine (500 MHz, 13C NMR, CDCl3).
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Figure C.5. EDTAHA arm (500 MHz, 1H NMR, DMSO).
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Figure C.6. EDTAHA arm (500 MHz, 13C NMR, DMSO).
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Figure C.7. EDTPHA arm (500 MHz, 1H NMR, CDCl3).
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Figure C.8. EDTPHA arm (500 MHz, 13C NMR, CDCl3).
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Figure C.9. EDTPHA, protected (500 MHz, 1H NMR, DMSO).
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Figure C.10. EDTPHA, protected (500 MHz, 13C NMR, DMSO).
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Figure C.11. EDTPHA, deprotecteed (500 MHz, 1H NMR, D2O)
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Figure C.12. EDTPHA, deprotected (500 MHz, 1H NMR, D2O).

175

Figure C.13. EDTBHA arm (500 MHz, 1H NMR, DMSO)
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Figure C.14. EDTBnHA arm (500 MHz, 1H NMR, DMSO).
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Figure C.15. EDTBnHA arm (500 MHz, 13C NMR, DMSO).
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Figure C.16. EDTBnHA, protected (500 MHz, 1H NMR, CDCl3).
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Figure C.17. EDTBnHA, protected (500 MHz, 13C NMR, CDCl3).
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